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Inflammation is considered to be the underlying cause of a majority of clinical 
disorders.  Thus, studies aimed at understanding the signaling pathways that trigger 
inflammation could have significant translational impact. In the current study, we 
investigated the effect of activation of cannabinoid (CB) and Aryl hydrocarbon 
hydroxylase (AhR) receptors on the inflammatory response.  To that end, we used 
cannabinoids such as ∆ (9)-Tetrahydrocannabinol (THC) and cannabidiol (CBD), and a 
well-established AhR agonist namely 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD). 
These were tested against two inflammatory disease models: 1) Experimental 
autoimmune encephalomyelitis (EAE), an animal model for human multiple sclerosis 
(MS), and 2) Exposure to pertussis toxin (PTX), an exotoxin produced by the bacterium, 
Bordetella pertussis, which causes whooping cough. We observed that combination of 
THC and CBD resulted in attenuation of EAE clinical scores and reduced 
proinflammatory cytokines secretion like IL-17A, IFN-γ, IL-6, TNF-α and IL-1β in the 
mononuclear cells of the brain.  Treatment of EAE mice with cannabinoids also led to 
decrease in immune cell infiltration in the CNS, marked amelioration of CNS tissue 
destruction, and reduced demyelination when compared to control mice.  Additionally, 
treatment with these cannabinoids led to cell cycle arrest and cell death in activated T 
cells. MicroRNA (miRNA) microarray analysis, revealed altered miRNA profile in brain 
infiltrating mononuclear cells following treatment with combination of THC and CBD 




mice caused alterations in gut microbiota with a decrease in the population of 
Akkermansia muicinphila, the bacteria that are increased in MS patients and involved in 
the pathogenicity of MS.  In addition, THC+CBD treatment increased the production of a 
wide range of short-chain fatty acids (SCFAs) that are anti-inflammatory.  In mice treated 
with PTX, there was significant induction of inflammation with an increase TH17 and 
TH1 proliferation.  AhR activation in PTX-treated mice with TCDD, led to increased 
induction of FoxP3+ Treg cells and myeloid-derived suppressor cells (MDSC) that are 
highly immunosuppressive. In addition, TCDD altered the expression of microRNAs that 
promoted anti-inflammatory T cell phenotype.  Together, the current study demonstrates 
that activation of CB and AhR on immune cells leads to epigenetic modulations as well 
as alterations in microbiota that promote anti-inflammatory signaling pathways.  The 
current study suggests that targeting CB and AhR constitutes a unique therapeutic 
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1.1 MULTIPLE SCLEROSIS 
Multiple Sclerosis (MS) is the most autoimmune inflammatory disease of 
autoimmune originate that affects the central nervous system (1-5). The demyelination 
effect this disease causes to the sheath which covers the nerves, damages the signals 
between the central nervous system (CNS) and the rest of the body, starting a massive list 
of symptoms that patients with MS suffer from. The precise cause of MS is still 
mysterious, yet its prevalence and incidence rates are increasing worldwide (6). It 
believes that environmental, genetic factors, and exogenous are the primary agents 
responsible for MS development (4). MS affects about 400,000 people in the US and 
close to 2.1 million people worldwide (7). MS is three times prevalent in women than 
men; it affects young people during their 20s and impairs their quality of life (7-9). 
Symptoms that disturb the quality of life may include fatigue, depression, reduced 
mobility, balance, numbness, pain, spasticity, cognitive impairment, dementia, vision , 
and bladder dysfunction(7). Several studies in Europe connect the mortality rate in 
multiple sclerosis patients with suicide after they noticed that it increased compared to 
other general populations (10). MS treatments that are available nowadays don’t show 
any significant relief to the patients besides having immunotoxicity side effects (11). 
Additionally, this disease is still a diagnostic challenge, and the lack of quick and 





(12). Currently, existing biomarkers for MS diagnosis and management have inherent 
limitations; that is why additional new biomarkers are required (13). Although the 
etiology of MS has not been uncovered yet, scientists found that CD4 T cells involved in 
its pathogenicity (11). CD4+T cells infiltrate across the blood–brain barrier (BBB) and 
promote inflammation, gliosis, neuroaxonal degeneration and demyelination leading to 
disruption of neuronal signaling. CD4+T cells infiltrate across the blood-brain barrier 
(BBB) and promote inflammation, gliosis, neuroaxonal degeneration, and demyelination 
leading to disruption of neuronal signaling. Differentiated CD4+ T helper 1 (TH1) and 
TH17 cells can infiltrate the CNS, leading to inflammation and tissue damage. In 
multiple sclerosis murine model, experimental autoimmune encephalomyelitis (EAE): 
emulsified central nervous system antigen is administered along with immune stimulants, 
leading to the generation of pathogenic CD4 T helper 1 (TH1) cells and TH17 cells in the 
lymph nodes. These cells then enter the circulation and eventually exert their effector 
functions in the CNS. CD4+ TH1 and TH17 cells then trigger the production of pro-
inflammatory cytokines and chemokines that initiate the inflammatory response in the 
CNS. 
1.2   MARIJUANA/CANNABINOIDS 
Marijuana Cannabinoids are active components of Cannabis sativa, an annual 
herbaceous plant they have been used by many cultures for centuries in medicine (14-17). 
Many studies have been done to investigate the active role of these components and 
others extracted from this plant. Studies showed the anti-inflammatory and 
neuroprotective effects of Cannabinoids, which are effective in the treatment of several 





chemical components have been extracted from Cannabis Sativa, 80 of them find only in 
this plant, and they don't in any other plant.  Also, over 60 components are cannabinoids 
(21). ∆(9)-Tetrahydrocannabinol (THC) is one of the major psychoactive constituents of 
cannabinoids derived from the Cannabis sativa plant and is known for its anti-
inflammatory properties(22, 23). THC is well known for its immunoregulatory 
properties. Precisely, regarding T cell activation, THC treatment has been shown to 
reduce proinflammatory cytokines, including TNF-α and IFN-γ, and suppress 
proliferation of T cells through apoptosis and induction of regulatory immune cells (24-
26). Also, THC is highly effective as a treatment in many models of T cell-driven 
inflammatory diseases, including autoimmune hepatitis, allogeneic hematopoietic cell 
transplantation, and inflammatory lung injury.(22, 26, 27). 
CBD is another important cannabinoids component, a non-psychoactive cannabinoid 
that might be used to moderate effects of THC in the therapeutic setting by providing 
protection from the acute and permanent cognitive effects of THC (28). CBD has been 
shown to exhibit anti-inflammatory properties (29). After many clinical trials, the 
combined of THC and CBD oral/mucosal spray Sativex was approved in Canada for 
spasticity that associated with multiple sclerosis (23, 30-32). Using marijuana, 
particularly THC and CBD for therapeutic purposes continues to expand where there is a 
growing scientific evidence for specific applications in autoimmune diseases like 
multiple sclerosis (23). Studies showed that THC exerts its effects through CB1and CB2 
receptors (15). Unlike THC, CBD does not bind and activate CB1 and CB2 receptors 
because CBD itself has no affinity for these receptors, but it can act as a negative 





receptors such as 5-HT(1A), TRPV1 or GPR55.  Both CB1 and CB2 are coupled to G-
proteins where CB1 receptor presents in the central nervous system as well in the 
immune cells, while CB2 receptor represents in specific peripheral tissues, mainly the 
immune cells. THC shows its immunomodulated effect through CB1 and CB2 receptors, 
but CBD works indirectly through CB2 receptor (20).  
1.3 THE ENDOCANNABINOID SYSTEM 
Endocannabinoids are a collection of bioactive lipids that might help as secondary 
modulators, which when mobilized coincident with first-line immune modulators, either 
increase or decrease many immune functions. Endocannabinoids lipid mediators are N-
arachidonoylethanolamine (anandamide, AEA) primarily isolated from porcine brain and 
2-arachidonoylglycerol (2-AG) primarily isolated from canine intestines, which are the 
first to be discovered and extensively studied (33-35). Additionally, they considered as 
endogenous ligands for the cannabinoid receptors, CB1, and CB2 (36).  AEA is 
responsible for preserving basal endocannabinoid signaling, binding to both the CB1 and 
CB2 receptors.  In contrast to AEA, 2-AG functions as a full agonist for both CB1 and 
CB2. Furthermore, Anandamide and 2-arachidonyl glycerol (2-AG) bind to G protein-
coupled cannabinoid receptors CB1 and CB2, respectively. These mediators show the 
immunosuppressive effect of cannabinoids. 
1.4 MICRORNAS 
        MicroRNAs (miRNAs) are short non-coding, single-stranded regulatory RNAs (on 
average, 22 nucleotides in length) that regulate gene expression at the post-transcriptional 
level (33, 34). miRNA bind primarily to the 3′-UTR of their respective target mRNA, 





encoded protein (35, 36). miRNAs have developed much attention because they control 
the expression of up to 30% genes and may play an essential role in the development of 
many complex diseases (9). Recent studies showed that miRNAs play important roles in 
a variety of physiologic and pathologic processes, most notably autoimmune diseases and 
cancer (37, 38). Several studies have demonstrated a role for miRNA in modulating 
immune responses under various inflammatory diseases (26, 39). miRNA dysregulation 
may contribute to the pathogenesis of multiple sclerosis (40). Identification of novel 
biomarkers and targets, for example, microRNAs, is beneficial to understand the 
pathogenetic mechanisms in a disease such as multiple sclerosis (41). Keller et al. found 
that the miRNA expression profiles in blood cells may serve as a biomarker for MS, and 
deregulation of miRNA expression may play a role in the pathogenesis of this disease 
(42). Moreover, mice deficient in miR-155 are resistant to developing experimental 
autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis while the 
overexpression of miR-155 exacerbates the symptoms associated with the disease (19) 
(13). Collectively, these studies strongly suggest that miRNAs play a principal role in 
controlling immune cell activation, mostly T cells, in addition to promoting 
proinflammatory responses (26). 
1.5 MICROBIOME AND MULTIPLE SCLEROSIS 
 Several environmental factors can affect immune function. Human healthy flora 
consists of bacteria, fungi, yeast, archaea, viruses, helminths, protozoa and parasites, that 
are mostly circulated in the internal cavity of our body, such as body surface, respiratory 
tract, digestive tract, urogenital tract, more than 95% of them situated in the large 





function of the host immunity (45). Furthermore, the commensal flora has significant 
effects on the control of systemic inflammation and the development of autoimmune 
disorders in animal models (43). Specifically, Gut microbiome dysbiosis has been 
demonstrated to significantly influence a range of disorders in humans, including 
rheumatoid arthritis, diabetes, obesity, and multiple sclerosis (MS)(46). MS is a complex 
neural disease and still not fully understood etiology (6, 47). Whereas certain genetic and 
environmental factors are involved (48). Changed gut microbiota might be one of the 
main missing ecological factors contributing to MS since evidence recommends that 
certain gut microbiota might be connected to either disease susceptibility or defense (49-
53). Furthermore, Studies found that metabolic deviation and alterations in the 
intracellular levels of specific metabolites are linked to the inflammatory phenotype of 
immune cells involved in autoimmune disorders such as rheumatoid arthritis, systemic 
lupus erythematosus, diabetes and multiple sclerosis (MS) (54). Short-chain fatty acids 
(SCFAs), the primary metabolites produced by bacterial fermentation of dietary fiber in 
the gastrointestinal tract, are estimated to have a critical role in microbiota-gut-brain 
linking(55). In recent years, the gut microbiota and fermentative metabolites like short‐
chain fatty acids (SCFAs) have received increased attention in relation to the 
development and disease course of MS (56, 57). Additional investigations are required to 
clarify the involvement of the gut microbiota and its metabolites, including potential 
useful effects of SCFAs, in the development and course of MS. 
1.6 PERTUSSIS TOXIN AND INFLAMMATION 
 Pertussis toxin (PTX) is a multisubunit protein toxin excretes exclusively by 





besides the adenylate cyclase toxin. Bordetella pertussis is the bacterial agent of the 
pertussis disease or whooping cough (59). PTX is conveyed across the bacterial outer 
membrane via a type IV secretion system encoded by the ptl genes (58, 59). PTX has a 
broad range of effects on host cell activities because of its inhibitory effect on G-protein-
coupled receptor pathways (60). During the peak of pertussis disease, and due to the PTX 
activity, the gene expression of IL-17, TNF-α and IFN-γ was up-regulated, demonstrating 
a mixed Th1 and Th17 cells response (61). Additionally, PTX has a role in autoimmunity 
where it involves in exacerbating certain experimental autoimmune diseases in rodent 
models, like Experimental Autoimmune Encephalomyelitis (EAE), the animal model of 
multiple sclerosis in humans (62). PTX increases in the permeability of the blood-brain 
barrier to allow the autoreactive T cells access to the central nervous system, initiating 
EAE pathology (63). Furthermore, PTX induces IL-6 and IFN-γ production and enhance 
the generation of Th17 cells to boost EAE effects (64-66).  
1.7 AHR AND ROLE IN IMMUNE MODULATION 
The aryl hydrocarbon receptor (AhR) is a transcription factor best known as the 
ligand for the toxin 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). However, it also binds 
to other toxins and to endogenous ligands. Using gene expression profile analysis, murine 
Th17 cells were shown to express the AhR which is also an essential component in the 
development of both regulatory T cells (Treg) and Th17 responses resulting in increased 
expression of IL-17 and IL-22 by Th17 cells (67). In another study, the AhR was shown 







1.8  TCDD (2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN) 
It is an extremely toxic environmental pollutant with a specific epigenetic 
carcinogen and a potential tumor promoter effects (69).TCDD belongs to the halogenated 
aromatic hydrocarbons compounds(70). TCDD is the most potent AhR agonist because 
of its strong binding affinity (Kd 10
−10–10−9 M) and resistance to metabolism (71). The 
aryl hydrocarbon receptor (AhR) was the first TCDD receptor to be studied (5). The aryl 
hydrocarbon receptor (AhR) is a significant cytosolic, ligand-activated receptor 
represented by different cells in many mammals.(72, 73). The AhR belongs to basic 
helix-loop-helix/Per-ARNT-Sim (bHLH-PAS) transcription factor families(5). AhR gene 
encodes a ligand-activated transcription factor over binding to halogenated aromatic 
hydrocarbons (HAHs) such as TCDD, as well as polynuclear aromatic hydrocarbons 
(PAHs) cause transformed gene expression and toxicity(74, 75). The AhR is necessary 
for T cells to generate Foxp3+ Treg cells(76). Also, AhR is critical for the formation of 
Tr1 cells in mice and humans, which inhibits autoimmune responses by interaction with 
the transcriptional factor macrophage-activating factor to improve the expression of IL-
10, IL-21, and IL-27(77). Additionally, AhR stimulation is involved in the promotion of 
Th17 to Tr1 transdifferentiation (78). 
1.9 HYPOTHESES 
 In the current study, we tested the central hypothesis that inflammation can be 
regulated through activation of CB receptors and AhR.   To that end, we used two models 
of inflammation:  EAE and PTX and used specific ligands for CB receptors 
(cannabinoids) and AhR (TCDD) to study epigenetic pathways involving miRNA, and 





1.9.1. Combination of cannabinoids, Δ9- tetrahydrocannabinol (THC) and cannabidiol 
(CBD) can ameliorate experimental autoimmune encephalomyelitis: 
1.9.1.1. Through modulation of the systemic or local pro/anti-inflammatory cytokine 
balance. 
1.9.1.2. By promoting cell cycle arrest and apoptosis in activated T cells through     
miRNA signaling pathways. 
1.9.1.3. By altering the gut microbiome. 
1.9.2. AhR activation can attenuate PTX-mediated systemic inflammation and regulation 
of the immune response occurs: 
1.9.2.1. Through modulation of the systemic pro and anti-inflammatory cytokine balance. 
1.9.2.2. By suppressing Th17 cell proliferation and induction of Treg production through 
miRNA signaling pathways. 







 COMBINATION OF CANNABINOIDS, Δ9 -
TETRAHYDROCANNABINOL AND CANNABIDIOL, 
AMELIORATES EXPERIMENTAL MULTIPLE SCLEROSIS BY 
SUPPRESSING NEUROINFLAMMATION THROUGH 
REGULATION OF MIRNA-MEDIATED SIGNALING PATHWAYS 
 
2.1 ABSTRACT 
Multiple sclerosis (MS) is a chronic and disabling disorder of the central nervous 
system (CNS) characterized by neuroinflammation leading to demyelination. Recently a 
combination of Δ9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) extracted from 
Cannabis has been approved in many parts of the world to treat MS-related spasticity.  
THC+CBD combination was also shown to suppress neuroinflammation, although the 
mechanisms remain to be further elucidated. In the current study, we demonstrate that 
THC+CBD combination therapy (10mg/kg each) but not THC or CBD alone, attenuates 
murine experimental autoimmune encephalomyelitis (EAE) by reducing 
neuroinflammation and suppression of Th17 and Th1 cells. These effects were mediated 
through CB1 and CB2 receptors inasmuch as, THC+CBD failed to ameliorate EAE in 
mice deficient in CB1 and CB2.  THC+CBD treatment also caused a decrease in the 
levels of brain infiltrating CD4+ T cells and pro-inflammatory molecules (IL-17, INF-γ, 
TNF-α, IL-1β, IL-6, and TBX21), while increasing anti-inflammatory phenotype such as 
FoxP3, STAT5b, IL-4, IL-10 and TGF-β.  Also, the brain-derived cells showed increased 





G2/M phase of cell cycle.  miRNA microarray analysis of brain-derived CD4+ T cells 
revealed that THC+CBD treatment significantly down-regulated miR-21a-5p, miR-31-
5p, miR-122-5p, miR-146a-5p, miR-150-5p, miR-155-5p, and miR-27b-5p while 
upregulating miR-706-5p and miR-7116.  Pathway analysis showed that majority of the 
down-regulated miRs targeted molecules involved in cycle arrest and apoptosis such as 
CDKN2A, BCL2L11, and CCNG1, as well as anti-inflammatory molecules such as 
SOCS1 and FoxP3.  Additionally, transfection studies involving miR-21 and use of 
Mir21-/- mice suggested that while this miR plays a critical role in EAE, additional miRs 
may also be involved in THC+CBD-mediated attenuation of EAE. Collectively, this 
study suggests that combination of THC+CBD suppresses neuroinflammation and 
attenuates clinical EAE development and that this effect is associated with changes in 
miRNA profile in brain-infiltrating cells. 
2.2 INTRODUCTION 
Multiple Sclerosis (MS) is chronic autoimmune disease that affects the central 
nervous system (CNS)(79-81). The incidence of MS is higher in women who are affected 
twice as often as men (82). Although the exact etiology of MS remains obscure, 
observational research has suggested that genetic and environmental factors may cause 
the onset and progression of the disease (83). Typically, MS is regarded as a T cell 
mediated autoimmune disorder, primarily driven by inflammatory Th1 and Th17 cells 
(83), (84). When autoreactive T-lymphocytes cross the blood brain barrier (BBB) and 
enter the central nervous system, they initiate local inflammation that results in 





Cannabinoids extracted from marijuana (Cannabis sativa), as well as synthetic 
forms have been well characterized for their anti-inflammatory properties (15). 
Cannabinoids have also been shown to ameliorate spasticity and neuropathic pain in MS 
patients (86), (87).  It is for this reason, a combination of Δ9 - tetrahydrocannabinol 
(THC) and Cannabidiol (CBD) has been approved as a drug (Sativex) in several countries 
including Europe, Australia and Canada (88). THC and CBD combination was tested 
recently in animal models of MS and was found to suppress neuroinflammation (89), 
(90).  However, the precise mechanisms, such as the role of miRNA, in the efficacy of 
such combination treatment remain to be elucidated further.  (THC) is well known for its 
psychoactive properties. It acts through CB1 receptors primarily expressed in the CNS 
and CB2 expressed predominantly on immune cells  (91).  Our laboratory and others 
have shown that THC increases anti-inflammatory and decreases pro-inflammatory 
cytokine production (16, 22, 26, 92) THC also mediates apoptosis in T cell driven 
inflammation, increases FoxP3+ Tregs through miRNA induction and epigenetic 
modifications(22, 26). On the other hand, CBD is a non-psychoactive phytocannabinoid, 
has also been shown to exhibit anti-inflammatory properties (29).   CBD has recently 
been approved by US FDA as a drug to treat epilepsy (91).  Unlike THC, CBD does not 
bind and activate CB1 and CB2 receptors but can act as a negative allosteric modulator of 
CB receptors (93).  Also, CBD has been shown to activate other receptors such as 
GPR55, TRPV1 or 5-HT1a (18, 94, 95).  Thus, it is possible that a combination of 
THC+CBD may be more effective in treating inflammation by targeting both 
cannabinoid CB1 and CB2 receptors as well as other potential receptors such as GPR55, 





MicroRNAs (miRNA, miR) are a class of short non-coding single-stranded RNAs 
19-24 nucleotides in length, involved in the post-transcriptional regulation of gene 
expression (81, 96, 97). miRNAs exert their regulatory role when they bind to the 3′ 
untranslated region (UTR) of target mRNA, eventually causing translational suppression 
through degradation or sequestration of mRNA (98) Several studies have detected the 
involvement of circulating miRNAs in physiological and pathological processes and 
identified them as potential biomarkers, therapeutic agents, or drug targets (99). 
Numerous miRNAs were found to be differentially expressed in patients with MS 
compared with controls and to have the potential to be used as diagnostic biomarkers or 
predictors of drug-response (100). Additionally, recent studies have shown crucial roles 
of specific miRNAs in controlling oligodendrocyte (OL) differentiation and myelination 
(101)  Dysregulation of miRNAs contributes to the pathogenesis of demyelinating 
diseases (102) . Moreover, new patents of miRNAs also provide new strategies for gene 
therapy and miRNA-drug development for demyelinating diseases, especially MS (103). 
Our lab has previously shown that cannabinoids can suppress inflammation in the 
periphery through regulation of miRNA(16) (81, 104). However, whether cannabinoids 
can alter the expression of miRs in the brain-infiltrating cells during EAE and whether 
such miRs contribute towards suppression of neuroinflammation has not been 
investigated.  In the current study, we used the combination of cannabinoids, THC and 
CBD, to address the potential ability of these components in ameliorating the symptoms 
and the progression of the disease in the EAE model, a murine model of MS. We 
demonstrate for the first time that the neuroprotective and anti-inflammatory properties of 





activated T cells as well as a switch of cytokines from pro-inflammatory to anti-
inflammatory, through altered expression of miRNAs.  
2.3 MATERIALS AND METHODS 
Mice 
C57BL/6 female mice aged 6-8-week-old and Mir21-/- mice were purchased from 
the Jackson Laboratory (Bar Harbor, ME). CB1-/-CB2-/- mice were bred in-house.  Mice 
were housed in a specific-pathogen-free facility at the University of South Carolina 
School of Medicine. All animal experiments were ethically performed according to the 
NIH guidelines and protocols approved by the University of South Carolina Institutional 
Animal Care and Use Committee. 
Reagents 
The reagents used in this study were purchased as described: THC and CBD from 
Cayman Chemical (Michigan. USA), myelin oligodendrocyte glycoprotein (MOG35-55) 
peptide H-MEVGWYRSPFSRVVHLYRNGK-OH (PolyPeptide Laboratories, San 
Diego, CA, USA). Mycobacterium tuberculosis (strain H37Ra) (BD, Franklin Lakes, NJ, 
USA), complete Freund’s adjuvant (Fisher, Hampton, NH, USA), Pertussis toxin (List 
Biological Laboratories, Campbell, CA, USA), Percoll, GE Healthcare Life Sciences 
(Pittsburgh, PA.USA); Neural Tissue Dissociation Kit (P) (Miltenyi Biotech, Auburn, 
CA.USA), RBC lysis buffer (Sigma-Aldrich, St. Louis, MO, USA), RPMI 1640, l-
glutamine, HEPES, phosphate-buffered saline, and fetal bovine serum (VWR, West 
Chester, PA, USA), ELISA Max Kits IL-10, IL-17A, IFN-, IL-6, IL-1β, TNF-α and 
TGF- and FITC Annexin V/ PI apoptosis kit (Biolegend, San Diego, CA).  EasySep PE 





(PI)/RNase Staining Solution (Cell Signaling Technology, Danvers, MA, USA), 
miRNeasy Mini Kit, miScript II RT Kit and miRNAs primers (Qiagen, Valencia, CA), 
mRNAs primers (Integrated DNA technologies, Coralville, IA. USA) and 
SsoAdvanced™ Universal SYBR® Green Supermix (Bio-Rad, Hercules, CA, USA). 
EAE induction, cannabinoid administration, and clinical assessment 
EAE was induced in female C57BL/6 mice (6–8 weeks old) through subcutaneous 
(s.c.) immunization in the hind flank with 100 μl of 150 μg MOG35-55 peptide 
(PolyPeptide Laboratories San Diego, CA. USA) emulsified in complete Freund’s 
adjuvant (Fisher, Hampton, NH, USA) containing 8 mg/ml killed Mycobacterium 
tuberculosis (strain H37Ra) (BD, Franklin Lakes, NJ, USA), as described previously(104, 
105) Following immunization, 200 ng of pertussis toxin (List Biological Laboratories, 
Campbell, CA.USA) was given to the mice by intraperitoneal injection on day 0, 
followed by 400ng on day 2. Control mice received CFA+PTX but not MOG.  To study 
the effect of THC+CBD treatment mice were randomized and treated with 10 mg/kg each 
THC and CBD or vehicle (2% dimethyl sulfoxide (DMSO) + 20% EtOH) diluted with 
sterile 1X PBS i.p. starting on day 10 after immunization and this treatment continued 
every day until the end of the experiment. Monitoring the animals and recording the 
clinical scores were done on a daily basis during the experiment. The mean of the score 
was calculated for each group every day. Clinical scores were recorded as follow: 0, 
healthy; 1, flat tail; 2, partial paralysis of hind limbs; 3, complete paralysis of hind limbs 
or partial hind and front limb paralysis; 4, tetraparalysis; 5, moribund; 6, death (106). 
Mice were provided daily with food and water (Boost and Hydrogel) in the cage floor 






Nociception is considered as one of the clinical markers of EAE(107). In the 
current study, we used the hot plate test to investigate nociception in unrestricted mice by 
placing each mouse on a platform surface which was maintained at 50°C. The response 
latency, which is the time taken to observe a nocifensive behavior that includes forepaw 
withdrawal or licking, hind paw withdrawal or licking, stamping, leaning posture and 
jumping, was recorded (108). 
Histopathology 
Perfused spinal cord tissues were isolated at 15 days post MOG immunization. 
Tissues were immersed in 4% paraformaldehyde for 24hr. Then paraffin blocks were 
prepared. Microtome sections (7 μm) were cut, and tissue sections were stained with 
Luxol Fast Blue (LFB) for detection of demyelination, in addition to haemotoxylin and 
eosin (H&E) staining for visualization of cellular infiltration. The images were acquired 
by Cytation 5 imaging reader (BioTek). 
Isolation of immune cells 
On day 15 post MOG immunization, inguinal lymph nodes (iLN) were excised 
from, EAE+Vehicle and EAE+(THC+CBD) prior to perfusion and were processed 
immediately to prepare single-cell suspensions. Then, mice were perfused slowly with 10 
mL heparinized PBS to get rid of contaminated blood. Whole brain tissues were isolated 
then homogenized separately into a single-cell suspension by using the Neural Tissue 
Dissociation Kit (P) (Miltenyi Biotech, Auburn, CA.USA) and red blood cell lysis buffer 
(Sigma-Aldrich, St. Louis, MO.USA). Mononuclear cells (MNC) from whole brain 





Percoll in FACS buffer (1X PBS, 2% heat-inactivated fetal bovine serum) (GE 
Healthcare Life Sciences, Pittsburgh, PA, USA). Cells were immediately counted and 
processed for further assays. 
Cell culture 
Brain MNCs and splenocytes cells were cultured for 24h in complete RPMI 1640 
media supplemented with 10% heat-inactivated fetal bovine serum, 10 mM l-glutamine, 
10 mM HEPES, 50 μM β-mercaptoethanol (Sigma-Aldrich St. Louis, MO.USA), and 
100 μg/ml penicillin/streptomycin at 37°C, 5% CO2, 95% humidity (104). Cell culture 
supernatants were collected for ELISA and/or cells were processed for flow cytometry, 
apoptosis and cell cycle assays. 
Detection of cytokines 
Brain and iLN were isolated from EAE+VEH and EAE+(THC+CBD) mice and 
processed to obtain single-cell suspensions, and 1 x 106 cells were cultured for 24 hours 
at 37°C, 5% CO2, 95% humidity as described (104). Cell culture supernatants were 
processed to detect interferon-γ (IFNγ), interleukin-17A (IL-17A), interleukin-6 (IL-6), 
Tumor Necrosis Factor-α (TNFα), interleukin 1β (IL-1 β), interleukin-10 (IL-10) and 
transforming growth factor- (TGF-) using ELISA kits following the manufacturer’s 
instructions (BioLegend, San Diego, CA). Absorbance at 450nm was read on a plate 
reader and concentrations were calculated using standard curves. 
Antibodies and flow cytometry 
Cells were stained with fluorochrome-conjugated antibodies and analyzed via BD 
FACS Celesta (San Jose, CA) to determine phenotypes of infiltrating brain mononuclear 





145-2C11), Brilliant Violet (BV785)-conjugated anti-CD4 (clone: GK 1.5), from 
Biolegend (San Diego, CA). 
Detection of (THC+CBD)-induced apoptosis in brain MNCs 
To determine if (THC+CBD) induces apoptosis in brain MNCs, cells were purified 
and cultured as described (104). After 24 hr incubation, cells were collected and washed 
twice with ice-cold 1X PBS, and then resuspended in Annexin V Binding Buffer at a 
concentration of 0.25-1.0 x 107 cells/ml. Next, 100 µl of cell suspension was transferred 
to a 5 ml flow tube. Next, 5 µl of FITC Annexin V and 10 µl of Propidium Iodide 
Solution was added.  The cells were gently vortexed and incubate for 15 min at room 
temperature in the dark. Finally, 400 µl of Annexin V Binding Buffer was added to each 
tube and analyzed by flow cytometry (BioLegend, San Diego, CA. USA). 
Cell cycle analysis 
Brain MNCs were cultured as described (104) . Cells were collected and stained 
with the PI/RNAs staining following the manufacturer’s instructions (Cell Signaling 
Technology, Danvers, MA. USA). The data were acquired by flow cytometry and 
analyzed with ModFit LT 3.3 (Verity Software House, Topsham, ME) after debris and 
doublets were gated out. 
CD4+ T cell selection 
Brain MNCs were labeled with Phycoerythrin (PE)-conjugated anti-CD4 (Clone: 
GK 1.5) antibody (BioLegend, San Diego, CA) then immunomagnetically selected with 
EasySep PE-positive selection kit according to the manufacturer instructions (StemCell 





by flow cytometry which was routinely > 90%. CD4+ T cells were lysed in Qiazol and 
stored at -80°C until RNA isolation (Qiagen). 
RNA isolation and cDNA synthesis 
Total RNA was purified from brain CD4+ T cells by using miRNeasy micro kit 
according to the manufacturer instructions and the concentration and purity of RNA were 
determined using the NanoDrop 2000 spectrophotometer from Thermo Scientific 
(Wilmington, DE). Next, the expression profiling of miRNAs using the Affymetrix 
GeneChip miRNA 4.0 array platform was performed as previously described (109)(. To 
validate miRNAs expression, the miScript cDNA synthesis kit used followed by 
quantitative real-time polymerase chain reaction (qRT-PCR) using the miScript SYBR 
Green PCR kit. Fold change of the interested miRNAs was determined using the 2-ΔΔCt 
method and expressed relatively to Snord96a. (Bio-Rad, Hercules, CA, USA). Validation 
of target genes expression, primers were purchased (Integrated DNA technologies, 
Coralville, IA. USA) and quantitative real-time polymerase chain reaction (qRT-PCR) 
was performed using SsoAdvanced universal SYBR Green supermix (Bio-Rad, Hercules, 
CA, USA). Fold change of the interested mRNAs was determined using the 2-ΔΔCt 
method and expressed relative to GAPDH. 
Transfection with miR-21a-5p mimic and inhibitor 
Splenic CD4+ T cells were purified by using the EasySep PE selection kit. The 
purity of the isolated cells was confirmed to be 97% CD4+ T cells by flow cytometry. 
Then cells were maintained for 24 hours in complete RPMI 1640 media supplemented 
with 10% heat-inactivated fetal bovine serum, 10 mM l-glutamine, 10 mM HEPES, 50 





Cells were seeded at 2 × 105 cells/well in a 24-well plate and transfected for 24 hours 
with mock control or 40 nM synthetic mimic or inhibitor oligonucleotides using 
HiPerFect transfection reagent (Qiagen, Germantown, MD) according to the 
manufacturer’s instructions. Total RNA and protein were extracted for analysis. 
Statistical analysis 
We performed statistical analysis using GraphPad Prism 8 (GraphPad Inc, La Jolla, 
CA). The data shown in this study represent at least three independent experiments to 
ensure consistency of findings. The statistical differences between groups were calculated 
using Student’s t-test for paired analyses or one- or two-way ANOVA for multiple group 
analyses. Mann–Whitney U test was performed to evaluate the extended clinical scoring 
in EAE mice, as described (104, 110). Statistical tests with post hoc tests are indicated in 
each figure legend.  A p value of ≤0.05 was considered significant. 
2.4 RESULTS 
Combination of THC and CBD attenuate the development of EAE 
Combination of THC+CBD has been used to treat human MS (111). This treatment 
is known to decrease not only muscle spasticity but also suppress neuroinflammation (89, 
90). To further investigate the mechanisms of suppression of neuroinflammation, we used 
murine model of EAE.  Mice were treated daily with THC alone (10mg/kg), CBD alone 
(10mg/kg), or a combination of THC+CBD (10mg/kg each) starting at 8-10 days after 
MOG immunization (Figure 1A).  Use of CFA+PTX as a control did not trigger any 
clinical signs of paralysis and furthermore, treatment of these mice with cannabinoids did 
not have any effect, thereby showing that the subsequent studies reported on EAE 





used CFA+PTX+MOG to induce EAE and study the effect of cannabinoids. The 
combination THC+CBD treatment resulted in attenuation of the clinical symptoms of 
EAE vs mice treated with Vehicle (VEH) (Figures 1C & 1D). Also, treatment with THC 
or CBD alone, at the doses tested, failed to cause significant suppression of clinical 
symptoms.  On day 14, the clinical scores were significantly reduced only in THC+CBD 
group but not in THC or CBD alone groups (Figure 1D).  These results indicated that the 
combination of THC+CBD was effective to treat mice with EAE. Based on these data, 
we focused our subsequent studies to combination treatment only.  Thus, an extension of 
the experiment until day 27 demonstrated that THC+CBD treatment was highly effective 
long-term at reducing clinical signs of EAE (Figures 1E & 1F).  
Next, we performed histological analysis on spinal cord tissues harvested at day 15. 
The spinal cord tissues from EAE+VEH mice showed elevated cellular infiltration vs 
Naïve mice when stained with H&E (Figure 1G). Also, extensive demyelination was 
observed in the white matter area with LFB staining in EAE+VEH vs Naïve mice (Figure 
1G). Both cellular infiltration and demyelination were reduced in spinal cord tissue of 
EAE+(THC+CBD) mice (Figure 1F). To test the role of CB1 and CB2 receptors in our 
model, we induced EAE in both wild-type (WT) and CB1-/-CB2-/- double-knockout mice, 
and then treated with THC+CBD.  Absence of cannabinoid receptors resulted in the 
inability of THC+CBD to reduce clinical scores of EAE (Figures 1H & 1I). The hot plate 
test was also performed to test the pain response and WT EAE+(THC+CBD) mice had 
increased withdrawal latency period indicating that cannabinoid receptor activation with 






Treatment with THC+CBD attenuates T-cell mediated inflammation in draining 
lymph nodes and brain 
 
Cell culture supernatants were isolated from draining iLN cells isolated at the peak 
of the disease. The cells were cultured at equivalent cellular density for 24hr and 
supernatants were assessed for the Th17 and Th1 pro-inflammatory cytokines, IL-17A 
and IFNγ, respectively. THC+CBD treatment reduced production of IL-17A and IFNγ in 
iLN (Figure 2A).  Additionally, flow cytometry analysis of encephalitogenic 
mononuclear cells (MNC) isolated from brain tissue showed decreases in the populations 
of total MNCs, CD3+ T cells, and of CD3+CD4+ Th cells in the EAE+(THC+CBD) 
group when compared to other experimental groups (Figures 2B & 2C).  Use of CB1-/-
CB2-/- double-knockout mice showed that the effect of THC+CBD in decreasing 
neuroinflammation was mediated through these cannabinoid receptors (Figures 2B & 2C) 
because THC+CBD was ineffective in these mice. 
miRNA analysis of THC+CBD treated EAE mice 
Because miRNAs play an important role in autoimmune diseases and 
neuroinflammation (112, 113), we investigated the role of miRNA in the THC+CBD-
induced attenuation of neuroinflammation in EAE mice. To that end, brain CD4+ T cells 
were isolated from mice treated with THC+CBD or vehicle as described earlier and used 
for miR microarray analysis. Of approximately 2000 miRNAs tested, 157 miRNAs were 
differentially expressed (Fold change > +/- 1.5) (Figure 3A). Proportional Venn diagram 
was generated to represent the fold change of the miRNAs that were up- or down-
regulated following treatment with THC+CBD in EAE mice (Figure 3B). A heat map 
generated showed different expression profile of miRNAs in the experimental groups 





with Ingenuity Pathway Analysis (IPA, Qiagen) and showed interaction with cell cycle, 
apoptosis, and T cell polarization molecules (Figure 3D). The microarray data and 
pathway analysis indicated several miRNAs that have been previously involved in the 
pathogenicity of MS such as, miR-31, -21a, -146a, -155 and -33(41) Quantitative RT-
PCR validated that THC+CBD treatment led to downregulation miR-21a-5p, miR-31-5p, 
miR-122-5p, miR-146a-5p, miR-150-5p, miR-155-5p, and miR-27b-5p (Figures 3E-3K). 
These miRNAs were found to directly target IL-10, FoxP3, SOCS1, Bcl2L11 and 
CCNG1 (Figure 3D and Table 1). THC+CBD treatment increased expression of miR-
706-5p and miR-7116 (Figure 3L-3M). The IL-17A gene was one of the hallmark genes 
that is targeted by miR-706-5p (Figure 3D and Table 1). Genes encoding TNF-α and IL-6 
were found to be targeted by miR-7116-5p (Figure 3D and Table 1). These genes play a 
pivotal role in EAE progression. Putative 3’ UTR targeting was analyzed for each 
miRNA-mRNA pairing using TargetScan alignment tools and microRNA.org (Table 1).  
Collectively, these data indicated that microRNA may have an integral role in the 
ameliorative effect of THC+CBD in EAE mice.  
Cytokine expression at gene and protein levels in EAE brain MNCs 
Pathway analysis identified miRNAs that targeted pro-inflammatory and anti-
inflammatory cytokines and Th subset transcription factors (Figure 3D). Expression of 
these target genes was validated by qRT-PCR (Figures 4A-4K). Treg related genes 
Foxp3, Stat5b, and IL10 were upregulated in EAE+(THC+CBD) brain-derived CD4+ T 
cells (Figures 4A-4C). Th2 related genes Gata3 and Il4 were also upregulated in CD4+ T 
cells following treatment (Figures 4D & 4E). Conversely, Th17 related genes Stat3 and 





Th1 related genes Tbx21 (encoding Tbet) and Ifng were downregulated in 
EAE+(THC+CBD) (Figures 4H & 4I). In addition, pro-inflammatory cytokines Il6 and 
Il1b were downregulated (Figures 4J & 4K). Cell culture supernatant of mononuclear 
cells from brain was used to evaluate cytokine production. In accordance with gene 
expression changes, IL-17A, IFNγ, TNFα, IL-6, and IL-1β production was reduced, while 
IL-10 and TGFβ production was increased in MNC supernatant from EAE+(THC+CBD) 
mice (Figure 4L). 
Detection of cell cycle arrest / apoptosis in brain MNCs 
miRNA array and pathway analysis also revealed that some pro-apoptotic and cell 
cycle arrest genes were targeted by downregulated miRs in EAE+(THC+CBD) mice 
including CDKN2A, SOCS1, Bcl2L11, and CCNG1 (Figure 3D). We validated 
upregulation of these genes by qRT-PCR (Figures 5A-5D).  Fold change was expressed 
relative to GAPDH. The primers used in the study are highlighted in Table 3. In addition, 
PI staining demonstrated that WT EAE+(THC+CBD) mice, in brain MNCs, had less 
cells in G0/G1 phase but more cells in G2/M phase of cell cycle when compared to WT 
EAE+Veh group (Figures 5E &5F). We also used a combination staining of Annexin V-
FITC with PI double-staining to identify early apoptotic (AnnexinV+/PI-) and late 
apoptotic cells (AnnexinV+/PI+). Late apoptosis was elevated in WT EAE-(THC+CBD) 
(Figures 5G & 5H).  In some of these experiments, we also used CB1-/-CB2-/- double 
knockout mice to test if the action of THC+CBD was mediated through cannabinoid 
receptors and we did find that to be true.  However, these mice showed some changes in 





mice, endocannabinoids were not able to act or that these mice had some compensatory 
mechanisms acting. 
Mir21-/- mice are more resistant to EAE than wild-type mice 
In our study, we found that THC+CBD treatment downregulated miR-21a-5p 
expression in brain CD4+ T cells (Figures 3C-3E).  To further address the role of this 
miRNA, we performed an in vitro miRNA transfection assay in CD4+ T cells and used 
qRT-PCR validation to test for miR-21 and target genes in cells transfected with mock, 
mimic or inhibitor (Figures 6A-6D). The data showed that use of miR-21 mimic led to a 
decrease in the expression of target genes while inhibitor caused significant induction of 
the target genes.  In addition, we also used mice deficient in miR-21.  Genotyping for the 
parents and the first generation of Mir21-/- mice (miR-21 KO) confirmed inactivation of 
the miR-21 gene (Figure 6E). To test the role of miR-21 in THC+CBD-mediated 
amelioration of EAE, we induced EAE in WT and Mir21-/- mice then treated with 
THC+CBD when symptoms appeared. The clinical scores revealed that Mir21-/- mice had 
less disease severity when compared with WT EAE mice (Figures 6F and 6G). Treatment 
with THC+CBD in Mir21-/- mice further reduced clinical symptoms of EAE similar to 
WT EAE+(THC+CBD) (Figures 6F & 6G). We performed cell cycle analysis in brain 
MNCs stained with PI to detect cell cycle by flow cytometry. The EAE-induced Mir21-/- 
mice were more similar to EAE+(THC+CBD) group in that these mice showed less cells 
in G0/G1 phase and more cells G2/M phase and furthermore, THC+CBD treatment in 
these mice failed to further cause significant changes in cell cycle thereby showing that 





Because Mir21-/- mice were more resistant to EAE when compared to WT mice, 
these data suggested that miR-21 does play a critical role in EAE and therefore, 
THC+CBD mediated down-regulation of miR-21 may play a role in cannabinoid-
mediated attenuation of EAE. However, when we treated Mir21-/- mice with THC+CBD, 
we found that these mice exhibited further reduction in EAE thereby suggesting that 
additional miRNAs may also be involved in the efficacy of cannabinoids to suppress 
EAE.  
2.5 DISCUSSION 
MS is an immune-mediated inflammatory disease of the CNS (114, 115).  The 
precise mechanisms of pathogenesis of MS remain unknown, although environmental as 
well as genetic components are believed to participate in this demyelinating disease(116) 
Current treatments for MS often consist of immunosuppressive drugs with many side-
effects after prolonged use.  In the current study, we investigated the role of miRNA in 
the attenuation of EAE by a combination of cannabinoids, THC and CBD, and found that 
such a treatment altered the expression of miRNA in brain MNCs that targeted 
inflammatory pathways leading to decreased expression of inflammatory cytokines as 
well as promotion of cell cycle arrest and apoptosis in encephalitogenic T cells in brain.  
Recently, a combination of THC+CBD, extracted from Cannabis plant, named 
Sativex, has been approved to treat MS in over 28 countries, including Europe and 
Canada  to help improve muscle spasticity(111, 117).  It is noteworthy that in the current 
study, while we used a combination THC and CBD, these were pure compounds, whereas 
in Sativex, the THC+CBD extract from Cannabis also includes low levels potentially 





THC+CBD, called the ‘entourage’ effect. Thus, this finding constitutes a limitation in 
comparing our studies to Sativex.  Nonetheless, our studies also demonstrate that pure 
forms of THC+CBD can also serve as therapeutic modality in the treatment of MS.  We 
and others have shown that both THC and CBD are potent suppressors of inflammation 
in a variety of autoimmune and inflammatory disease models (16, 26). Thus, it is likely 
that THC+CBD combination can also suppress neuroinflammation, in addition to 
suppressing muscle spasticity. In fact, recent studies demonstrated that THC+CBD 
combination can attenuate EAE by suppressing neuroinflammation (89, 90)and our study 
further supports this finding.  It should be noted that we and others have shown that THC 
and CBD when used alone, can suppress EAE (16, 19, 118, 119)  In the current study, we 
observed that CBD or THC when administered alone at 10mg/kg failed to suppress 
clinical scores in MOG-induced EAE.  We found in a previous study that a dose of 
20mg/kg of CBD was necessary to attenuate clinical signs in EAE (16) . There are 
limited studies on THC and the dose and efficacy may depend on the model of EAE, its 
use as preventive or treatment measure, the strain/species model used and the like (120)  
Nonetheless, we found in our current study, using cannabinoids after disease onset, that a 
single dose of CBD or THC at 10 mg/kg was not effective while a combination of these 
was highly effective in suppressing clinical symptoms and neuroinflammation in EAE.  It 
should be noted that in a previous study, the authors treated EAE mice with THC 
(20mg/kg), CBD (20mg/kg) or THC+CBD (10mg/kg each), daily from the day symptoms 
appeared till the first relapse of the disease and found that the three treatments delayed 
the onset of symptoms.  However, only THC+CBD or THC alone were able to attenuate 





current study is that we used lower doses of THC or CBD alone (10mg/kg) and we 
treated the mice for much shorter duration.  The reason for the design of our study was to 
identify the miRNA which would be induced early on and characterize them.  Thus, it is 
possible that if we had continued treatment with CBD or THC alone for the entire 
duration of the study, we could have found these to be effective.  
It is well-established that THC acts through CB1 and CB2 receptors while CBD 
does not bind to these receptors or binds with very low affinity but in vivo, may act 
through other receptors such as GPR55, TRPV1, 5-HT1a or PPAR-  (18, 94, 95)  
(121),(90).  Nonetheless, CBD can alter the uptake and breakdown of endocannabinoids 
thereby indirectly affecting the activation of CB receptors or it can mediate CB1 
antagonism (122, 123)  In the current study, we used mice deficient in CB1 and CB2 and 
found that these mice bearing EAE when treated with THC+CBD failed to exhibit EAE 
amelioration which suggested that THC+CBD treatment was acting through these 
receptors.  However, these mice showed similar levels of clinical disease as the wild-type 
mice.  This may be because they may exhibit some compensatory mechanisms or that the 
endocannabinoids in the absence of CB1 and CB2 may act on other receptors such as the 
vanilloid receptors (124)  To the best of our knowledge, there are no previous studies on 
the use of such double-knockout mice in EAE.  However, the use of mice deficient in 
CB1 or CB2 alone has provided evidence for the involvement of these receptors and 
endocannabnoids in EAE.  For example, mice deficient in CB1 receptor showed a more 
severe clinical course indicating that endogenous cannabinoids activate CB1 that helps 
control neuroinflammation and EAE (125)  Also, CB2 knockout mice were shown to 





failed to affect EAE in ABH mice (126). Such studies have raised some concerns about 
the translational value of some transgenic/gene knockout studies which may depend 
on susceptibility genetic backgrounds (127).  Additionally, the knockout mice may have 
different microbiota which may influence EAE as shown in our studies in mice with 
CD44 deletion (128)  Thus, clearly, additional studies are necessary on use of CB 
receptor knock out mice in understanding the role of cannabinoids in EAE.   In the 
current study, the anti-inflammatory properties of THC+CBD were evident in their ability 
to decrease the expression of pro- inflammatory cytokines (IL-17A, IL-6, TNF-α, IFNγ 
and IL-1β) induced in EAE.  Also, Chalah MA et al. found that the pro-inflammatory 
cytokines IL-6, TNF-α, and IFNγ are related to MS fatigue, which is one of the distinct 
symptoms that the MS patients are suffering from(129) T-bet is a Th1 cell-specific 
transcription factor that controls the expression of the hallmark Th1 cytokine, IFN-γ  
(130)  In our study we found that its expression was repressed along with other cytokine 
transcription factors of IL-17A, IL-6 and TNF-α after treatment with the THC+CBD, 
which demonstrate the inflammatory suppressive role of the cannabinoids. Increased 
GATA-3 expression plays an important role in enhancing IL-4 production in 
differentiated Th2 and inhibiting Th1 differentiation (131)  On the other hand, we also 
found that the cannabinoids increased the expression of the anti-inflammatory cytokines 
(IL-10 and TGF-β).  It has been reported that the deficiency or abnormal expression of 
IL-10 can increase inflammatory response to microbial challenge but also lead to 
development of inflammatory bowel diseases (IBDs) and several autoimmune diseases 
(132, 133) Overall, our data are consistent with the previously reported studies 





suppressing Th1 cells (22, 25, 134) Our previous studies have also identified the 
mechanisms through which cannabinoids such as THC suppress cytokine production.  
One of the mechanisms include epigenetic modifications in which THC treatment leads 
to the association of active histone modification signals to Th2 cytokine genes and 
suppressive modification signals to Th1 cytokine genes, leading to a switch from Th1 to 
Th2 (135)  
We have previously shown that miRNA play a critical role in cannabinoid-
mediated suppression of inflammation.  In delayed-type hypersensitivity (DTH) model, 
we noted that THC suppressed Th17 cell differentiation through suppression of miR-21 
expression, which induced SMAD7 consequently suppressing Th17 (22) THC also 
caused downregulation of miR-29b, an IFN-γ inhibitor.  THC treatment reversed this miR 
dysregulation. Additionally, when we transfected primary cells from DTH mice with 
miR-21 inhibitor or miR-29b mimic, there was an increase in SMAD7 and decrease in 
IFN-γ expression, respectively.   In the current study, we observed downregulation of 
miR-155 in EAE mice treated with THC+CBD. Recent studies have focused on the 
participation of miR-155 in EAE. MiR-155 mediates inflammatory response through 
promoting the development of inflammatory Th1 and Th17 cells. Furthermore, miR-155 
has been involved in inhibiting the protein suppressor of cytokine signaling 1 (SOCS1) in 
activated CD4+ T cells (136) Mice lacking miR-155 (mir-155-/-) have reduced EAE 
disease severity accompanied by less CNS inflammation and decreased Th1 and Th17 
responses (136) In addition, in the current study, we also noted that cannabinoid 
treatment led to down-regulation of miR-31, which targeted FoxP3.  This is consistent 





natural Tregs (137) Also, it has been shown that conditional deletion of miR-31 leads to 
an increase in peripheral Tregs and reduced severity of EAE (138)  
Studies from our laboratory have shown that THC and CBD when tested 
individually can trigger apoptosis in immune cells as well as in some cancer cell lines 
(94) (17, 139-141) However, roles of miRNA in the regulation of cannabinoid-mediated 
apoptosis in immune cells are not clearly understood, especially with respect to MNCs 
isolated from the brain during neuroinflammation.  In the current study, we noted that 
THC+CBD treatment led to significant increase in apoptosis in brain MNCs, which also 
showed decrease in G0/G1 phase of cell cycle and increase in G2M phase.  Our results 
demonstrated that THC+CBD treatment caused downregulation of some miRNAs like 
miR-122-5p and miR-21a-5p, which may target genes that regulate cell cycle arrest and 
apoptosis such as Bcl2L11, CCNG1 and CDKN2A, which were found to be upregulated. 
Moreover, treatment with THC+CBD led to upregulation of miRNAs such as miR-706-
5p. It has been reported that miR-706-5p affects the expression of cell division cycle 
associated 4 gene, Cdca4, a gene that is important for cell cycle G1 phase progression 
specifically through the E2F/retinoblastoma protein pathway (142) Also, miR-706-5p 
downregulates the activity of Cacul1, which is a cell cycle associated protein capable of 
promoting cell proliferation through the activation of CDK2 at the G1/S phase 
transition(143) In addition, some of the miRNA may also target FoxP3 expression.  For 
example, our pathway analysis showed that miR-31 may regulate FoxP3 consistent with 
previously published findings that this miR negatively regulates FoxP3 expression in 
Tregs (137).  Interestingly, we noted that THC+CBD treatment led to significant down-





While THC+CBD treatment led to alterations in many miRNAs, we further focused 
our studies on Mir-21.  We observed that Mir21-/- mice were more resistant to EAE when 
compared to WT mice; these data suggested that miR-21 does play a critical role in EAE.  
These data are consistent with previous studies showing that miR-21 deficiency leads to 
increased resistance to EAE (144) Because our data also demonstrated that THC+CBD 
treatment caused down-regulation of miR-21, these data together suggested that miR-21 
may play a critical role in cannabinoid-mediated attenuation of EAE.   However, when 
we treated Mir21-/- mice with THC+CBD, we found that these mice exhibited further 
reduction in EAE thereby suggesting that additional miRNAs may also be involved in the 
efficacy of cannabinoids to suppress EAE.   
In conclusion, this combination therapy resulted in alleviation of the clinical 
symptoms of EAE, a mouse model of human MS. Treatment of THC+CBD resulted in 
reduction of the clinical signs of disease, reduction in pro-inflammatory cytokine 
production, and decreased inflammatory infiltration of cells into the CNS, which prevents 
the hallmark of disease progression, which is the demyelination of neuronal cells. Acting 
in a neuroprotective manner, we observed that THC+CBD induced apoptosis and cell 
cycle arrest (G2/M) in brain-infiltrating cells. From a mechanistic standpoint, we found 
that this combination therapy leads to dysregulation of several miRNA, post-
transcriptional modifiers of gene expression. We were able to correlate this miRNA 
dysregulation to several features of cellular pathways, such as apoptosis and cell cycle 
arrest. Specifically, in the current study we show decreased expression of miR-21 
correlates with increased expression of the target Bcl2L11, a pro-apoptotic factor 





Figure 2.1 Combination of THC+CBD attenuates EAE by suppressing 
neuroinflammation. EAE was induced in C57BL/6 mice using CFA+PTX+MOG, as 
described in Methods.  These mice were treated with cannabinoids and the mice were 
studied for clinical signs of paralysis and neuroinflammation. (A) Experimental timeline. 
EAE mice were treated daily with THC (10mg/kg), CBD (10mg/kg), or a combination of 
THC+CBD (10mg/kg each) starting at 8-10 days after MOG immunization. (B) Controls 
consisting of mice that received CFA+PTX only that received cannabinoids. (C&D) 
Clinical scoring of EAE symptoms in mice treated with Veh, THC, CBD, or THC+CBD. 
(E&F) EAE scoring in an extended experiment until day 27 in Veh vs THC+CBD treated 
EAE mice. (G) Representative H&E images and LFB staining in spinal cord tissues to 
detect cellular infiltration and demyelination, respectively. (H&I) EAE scoring in WT or 
CB1-/-CB2-/- double knockout mice treated with either Veh or THC+CBD. (J) 
Withdrawal latency time during the hot plate test to quantify analgesic sensitivity. Data 
presented are mean +/- SEM. For (B-C & H), significance was determined by two-way 
ANOVA with a Dunnett post hoc test. For (D & I), one-way ANOVA with a Dunnett 
post hoc test was used. For (E) Mann-Whitney U test was performed excluding scoring 
values before initiation of treatment. For (F), an unpaired two-tailed T-test was 






Figure  2.2 T cell population and phenotypic changes of WT and CB1-/-CB2 -/- EAE 
mice treated with vehicle or THC+CBD. As shown in Figure 1, EAE was induced in 
naïve mice then mice were treated with Veh or THC+CBD when symptoms appeared. 
Inguinal lymph nodes and brain MNCs were collected at the peak of disease (Day 15 post 
immunization). (A) IL-17A and IFNγ concentration in inguinal lymph node 24h culture 
supernatant measured by ELISA. (B) Representative flow cytometry contour plots of 
encephalitogenic T cells. (C) Quantification of total MNCs, CD3+ T cells, and 
CD3+CD4+ Th cells per brain. Data presented are mean +/- SEM. ***p<0.001, *p<0.05 






Figure 2.3   Differentially expressed miRNAs in brain-infiltrating CD4+ T cells upon 
THC+CBD treatment in EAE mice. Total RNA was isolated and pooled from CD4+ T 
cells obtained from the brains of EAE mice post-treated with vehicle (n = 5) or 
THC+CBD (n = 5) on day 15. MicroRNA microarray expression levels of differentially 
expressed miRNAs were generated. (A) The fold change distribution of all 1,908 
miRNAs tested. (B) Proportional Venn diagram illustrating fold change of miRNAs that 
were >1.5- fold dysregulated following treatment with THC+CBD in EAE mice. (C) 





were upregulated (red) and downregulated (green). (D) Pathway analysis of miRs 
mediating dysregulation in gene expression following THC+CBD treatment. (E-M) 
Expression levels of selected upregulated and downregulated miRNAs were validated by 
qRT-PCR using Snord96a as a small RNA endogenous control. Data presented are mean 






Figure 2.4  Expression of miRNA target genes involved in Th cell polarization. As 
described in Figures 2 and 3, CD4+ T cells or total MNCs were isolated from brains of 
EAE mice on day 15 post immunization. For panels A-K, RNA was extracted from 
CD4+ T cells and used for miR target gene validation. For panel L, total MNCs were 
cultured for 24h and supernatants were collected for cytokine analysis. (A-K) qRT-PCR 
validation of the target genes (A) Foxp3, (B) STAT5B, (C) IL-10, (D) GATA3, (E) IL-4 
(F) STAT3, (G) IL-17A, (H) TBX21, (I) IFN-γ, (J) IL-6 and (K) IL-1β using GAPDH as 
endogenous control. (L) IL-17A, IFN-γ, TNF-α, IL-6 IL-1β, IL-10 and TGF-β 
concentration measured in MNC culture supernatants by ELISA. Data are expressed as 
the mean ± S.E.M. and statistical significance is indicated as ***p<0.001, **p<0.01 by 






Figure 2.5 THC+CBD treatment induces cell cycle arrest / apoptosis in brain MNCs. 
As shown in Figure 1, EAE was induced in naïve mice and treatment with Veh or 
THC+CBD was initiated at the onset of symptoms. CD4+ T cells and total MNCs were 
isolated from the brains of mice on day 15 post immunization for gene and cell cycle 
analysis. (A-D) qRT-PCR validation of miR target genes involved in cell cycle/apoptosis. 
(E) Representative flow cytometry histograms of PI staining in brain MNCs using 
ModFit software. (F) Cell cycle phase quantification. (G) Representative flow cytometry 
pseudocolor plots of brain MNCs in early apoptosis (AnnexinV+PI-) or late apoptosis 
(AnnexinV+PI+). (H) Quantification of brain MNCs in early or late apoptosis. Data 
represented are mean +/- SEM. ***p<0.001, **p<0.01 by unpaired two-tailed T test (A-







Figure 2.6 Role of miR-21a-5p downregulation on THC+CBD-mediated 
amelioration of EAE. For (A-D), miR-21a-5p transfection assays were performed in 
CD4+ T cells purified from naïve WT C57BL6 mice. Cells were cultured for 24h and 
transfected with miR-21a-5p mimic, inhibitor, or mock (transfection reagent only). 
For (E-F) EAE was induced in WT and Mir21-/- mice as described in Methods then 
treated with Veh or THC+CBD upon development of EAE symptoms.  (A-D) qRT-
PCR validation for miR-21 and the target genes. (E) Agarose gel electrophoresis of 
genotyping for the parents and the first generation of Mir21-/- mice (miR-21 KO). (F) 
EAE scoring in WT and Mir21-/- mice. (G) Quantification of the clinical scores. (H) 
Representative flow cytometry histograms of brain MNCs stained with PI study cell 
cycle analysis.  (I) Quantification of cell cycle phases. Data are expressed as the mean 
± S.E.M. and statistical significance is indicated as ***p<0.001, **p<0.01, *p<0.05. 
For (F), statistical significance is vs. WT EAE+Veh. Significance was determined by 









CCNG1   




                      |||||||  PhastCons 
score: 
0.5536 
1796:5' uuaggcuugauaaaACACUCCa 3' Ccng1  




                ||| ||   |||||||  PhastCons 
score: 
0.4986 
 921:5' agaacgaaGAACUCCCAAGUUCUCu 3' Ccng1  




                               ||| | |   |||||||  PhastCons 
score: 
0.5944 
1306:5' uguGAAAUAA--AACUGUGAa 3' Ccng1  




                      |||||||  PhastCons 
score: 
0.5536 
1682:5' aaauuugucagaacUGCUGCUu 3' Ccng1  




          ||| | | | | |||||||  PhastCons 
score: 
0.5917 
1226:5' ucCUGAUUCUAAGCUUGGGAGa 3' Ccng1  
CDKN1b   













           |:| :|||:| |||||||  PhastCons 
score: 
0.537 
1093:5' cuuAUAAUAGUUU-AUAAGCUc 3' Cdkn1b  




           :||| | | |||   |||||||  PhastCons 
score: 
0.537 
1236:5' aagGAAUAUAGAGAUGGCACAGGGUu 3' Cdkn1b  




           | ||  ||  || ||||||  PhastCons 
score: 
0.5328 
1376:5' aagUUGUCGAAUUGGAUGGGAGu 3' Cdkn1b  




          :::||  |:: ||:||||||  PhastCons 
score: 
0.5372 
1811:5' caUUUUAGAAUGUUUGGCAUUAu 3' Cdkn1b  




           | | || || | ||||||  PhastCons 
score: 
0.5482 
 232:5' uucCCAAGCAAG-AACUUGCCa 3' Cdkn1b  
Bcl2l11   




                 | || :||||||  PhastCons 
score: 
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           |:||:|  || |||||||  PhastCons 
score: 
0.546 
1814:5' uguAUAUUA-CCU-AUAAGCUu 3' Bcl2l11  




                        ||||||  PhastCons 
score: 
0.5603 
 785:5' augcgcagcuucagccCAGGGUa 3' Bcl2l11  
IL10   




                       ||||||  PhastCons 
score: 
0.6418 
 290:5' gauuauauuauaugaUGGGAGg 3' Il10  
     3' uuGGGUACCUUAAGUCAAGAgu 5' mmu-miR-146a mirSVR 
score: 
-0.586 
          | | |  |||| ||||||   PhastCons 
score: 
0.7581 
 578:5' acCACCUAAAAUU-AGUUCUaa 3' Il10  
     3' aguuguagucagacuAUUCGAu 5' mmu-miR-21 mirSVR 
score: 
-0.155 
                       ||||||  PhastCons 
score: 
0.6617 
 233:5' uuuuuaaccuguguuUAAGCUg 3' Il10  




           :|||| ||  :|||||||  PhastCons 
score: 
0.6418 








     3' uuGGGUACCUUAAGUCAAGAgu 5' mmu-miR-146a mirSVR 
score: 
-0.586 
          | | |  |||| ||||||   PhastCons 
score: 
0.7581 
 578:5' acCACCUAAAAUU-AGUUCUaa 3' Il10  




             ||| |||  | ||||||  PhastCons 
score: 
0.6709 




     3' uccguaUCCUACUGUUUC-CCUu 5' mmu-miR-204 mirSVR 
score: 
-0.194 
              || | || |||| |||  PhastCons 
score: 
0.5948 
 896:5' gaucccAGCAGGAGAAAGCGGAu 3' Foxp3  




                       ||||||  PhastCons 
score: 
0.7094 
 695:5' guaccccacgucucaCUUGCCa 3' Foxp3  




          |:::| || ||||| |||||  PhastCons 
score: 
0.5291 
  97:5' acCGGGCGAUGAUGUGCCUGCUa 3' Foxp3  














1243:5' guauguccuucccucCACUCCa 3' Foxp3  
IL17a   
     3' aaaaaacucuguccCAAAGAGa 5' mmu-miR-706 mirSVR score: -0.6735 
                      |||||||  PhastCons 
score: 
0.4105 
  23:5' uaagaaacccccacGUUUCUCa 3' Il17a  
TNF  
5'  ...CCCAGUGUGGGAAGCUGUCUUCA… (Position 529-535)  Targetscan context score :-0.17 
                      |||||||   
3'       AAAAAAAAGGACUACAGAAGU mmu-miR-7116-5p Targetscan context++ score percentile: 86 
IL6  
5' ...UUAUAAUGUUUAGAC-UGUCUUCA… (Position 390-397)  Targetscan context score :-0.57 
              |||     |||||||   












miR-7116-5p                                                     UGAAGACAUCAGGAAAAAAAA GAAGACA     6.8 
miR-706 AGAGAAACCCUGUCUCAAAAAA GAGAAAC    10.4 
miR-122-5p                                                     UGGAGUGUGACAAUGGUGUUUG GGAGUGU   -25.8 
miR-21a-5p UAGCUUAUCAGACUGAUGUUGA AGCUUAU    -2.4 
miR-155-5p UUAAUGCUAAUUGUGAUAGGGGU UAAUGCU    -2.5 
miR-338-5p AACAAUAUCCUGGUGCUGAGUG ACAAUAU   -1.8 
miR-146a-5p UGAGAACUGAAUUCCAUGGGUU GAGAACU    -1.7 
miR-31-5p AGGCAAGAUGCUGGCAUAGCUG GGCAAGA    -4.7 
miR-27-5p AGGGCUUAGCUGCUUGUGAGCA GGGCUUA   -1.8 
miR-204-5p UUCCCUUUGUCAUCCUAUGCCU UCCCUUU    -6.5 












Primers Sequence (5′–3′) 
Il10 Forward: CCCATTCCTCGTCACGATCTC 
Reverse: TCCCATTCCTCGTCACGATCTC 
Tgfβ          Forward: ATGTCACGGTTAGGGGCTC 
Reverse: GGCTTGCATACTGTGCTGTATAG 
Il4 Forward: GGTCTCAACCCCCAGCTAGT 
Reverse: GCCGATGATCTCTCTCAAGTGAT 
Gata3 Forward: CTCGGCCATTCGTACATGGAA 
Reverse: GGATACCTCTGCACCGTAGC 
Il17a Forward: TTTAACTCCCTTGGCGCAAAA 
Reverse: CTTTCCCTCCGCATTGACAC 
Ifng           Forward: TCCTCGCCAGACTCGTTTTC 
Reverse: GTCTTGGGTCATTGCTGGAAG 
Tbx21           Forward: AGCAAGGACGGCGAATGTT 
Reverse: GGGTGGACATATAAGCGGTTC 
Il6              Forward: CCAAGAGGTGAGTGCTTCCC 
Reverse: CTGTTGTTCAGACTCTCTCCCT 
TNF-α Forward: GGAACACGTCGTGGGATAATG 
Reverse: GGCAGACTTTGGATGCTTCTT 
Foxp3 Forward: CCCATCCCCAGGAGTCTTG 
Reverse: ACCATGACTAGGGGCACTGTA 
SOCS1 Forward: CTGCGGCTTCTATTGGGGAC 
Reverse: AAAAGGCAGTCGAAGGTCTCG 
Bcl2L11 Forward: GACAGAACCGCAAGGTAATCC 
Reverse: ACTTGTCACAACTCATGGGTG 
CCNG1 Forward: ACAACTGACTCTCAGAAACTGC 
Reverse: CATTATCATGGGCCGACTCAAT 
CDKN2B Forward: CCCTGCCACCCTTACCAGA 
Reverse: CAGATACCTCGCAATGTCACG 
Cacul1 Forward: AACACCTCCACCTCCAAGTT 
Reverse: AGACTCGCTCTAAGTGGCTG 
Cdca4 Forward: GTAGAGGGTTTTGGCACTGTC 
Reverse: TGGGCTCCACTAGCATGTGA 
GAPDH Forward: TGGATTTGGACGCATTGGTC 
Reverse: TTTGCACTGGTACGTGTTGAT 
 







COMBINATION OF CANNABINOIDS, ∆9-
TETRAHYDROCANNABINOL (THC) AND CANNABIDIOL (CBD), 
MITIGATES EXPERIMENTAL AUTOIMMUNE 
ENCEPHALOMYELITIS (EAE) BY DIMINISHING THE GUT 
MUCINS DEGRADER BACTERIA 
 
3.1 ABSTRACT 
Multiple Sclerosis (MS) is one of the most common autoimmune diseases that affects 
the central nervous system (CNS). Currently there is no cure for patients suffering from 
MS, and most treatments involve the use of immunosuppressive drugs that can have 
adverse side effects or increased toxicity. Cannabis, traditionally known as marijuana, is 
a product of the Cannabis sativa, an annual herbaceous plant, and for several centuries, 
marijuana has been used as an alternative medicine in many cultures. Cannabis sativa has 
over 421 chemical compounds, including about 80 terpenophenol compounds named 
phytocannabinoids, which includes both delta-9-tetrahydrocannabinol (THC) and 
cannabidiol (CBD). In the currently study, we show a combination therapy of THC and 
CBD (THC+CBD) results in amelioration of experimental autoimmune 
encephalomyelitis (EAE), an animal model of MS, by reducing hind limb paralysis, 
decreasing immune cellular infiltration into the brain, and preventing the presence of 
inflammatory biomarkers. We performed 16S rRNA sequencing on bacterial DNAs 
extracted from the experimental groups to investigate the gut microbiome compositions 





that EAE mice showed a high abundance of mucin degrading bacterial species, such as 
Akkermansia muciniphila (A.muc), which was significantly reduced after THC+CBD 
treatment. Fecal Material Transfer (FMT) experiments confirmed that THC+CBD-
mediated changes in the microbiome helped attenuate EAE clinical scores. Collectively, 
our data suggests that THC+CBD can ameliorate disease by preventing EAE-associated 
microbial dysbiosis which is characterized by an accumulation of mucin-degrading 
bacteria such as A.muc. 
3.2 INTRODUCTION 
 Multiple sclerosis (MS) is a chronic neuroinflammatory and demyelinating 
autoimmune disorder of the central nervous system (CNS) mainly affecting young adults 
worldwide and it is more common in women than men (145). The pathogenesis of this 
disease includes development lead to demyelination. Although the complete etiology and 
the pathogenesis of MS remains unclear, there is evidence that increased migration of 
autoreactive lymphocytes across the blood-brain barrier (BBB) may be responsible for 
axonal demyelination of neurons, which results in axonal injury, oligodendrocyte loss, 
neuronal damage, and glial plaques (99). Experimental autoimmune encephalomyelitis 
(EAE), an animal model of MS, is often used to study disease development and is 
characterized by neurological dysfunction and demyelination closely mimicking 
conditions in the human MS patient population (146-148). Most current treatments of 
MS, such as interferon (IFN)-β, fingolimod, and glatiramer acetate act by regulating the 
immune response (99, 149, 150), however these drugs are only partially effective in many 
cases (20-30% successful in MS patients) and can have negative side-effects and 





patient population, new treatments are needed to improve the outcomes of patients who 
are affected by MS.  
 Cannabis is a product of Cannabis sativa, an annual herbaceous plant, and for 
several centuries this plant product has been used as an alternative medicine in many 
countries (153). Cannabis sativa produces over 421 chemical compounds, including 
about 80 terpenophenolic compounds named phytocannabinoids, which include both 
THC and CBD (14). Research has shown cannabinoids are effective treatment options 
against neurodegenerative diseases, including MS, because these plant products can 
reduce disease-associated effects such as oligodendrocyte death and axonal damage (15, 
154). In addition, THC+CBD combination therapy has been shown to effectively reduce 
MS-associated tremors and spasticity, leading to ongoing human clinical trials (155-158). 
Cannabinoids have also been shown to exert potent anti-inflammatory activities, 
particularly through regulating immune cells involved in the innate and adaptive immune 
response (15-17, 22, 159). More recent reports are exploring the role cannabinoids have 
in regulating the gut microbiome, a major player in overall human host health and disease 
(160-163).  
The microbiome, consisting of a large population of commensal microbes, plays 
such an important role in the health of the host it has been referred to as the “forgotten 
organ” (164). Studies of MS patients and the EAE mouse model of MS have shown the 
gut microbiome plays a significant role in disease both progression and severity (46, 165, 
166). For example, it was found that germ-free mice developed a less severe EAE disease 
with a reduction in pro-inflammatory IFN-γ and IL-17A T cell responses accompanied 





recent study has shown that unaltered commensal bacteria can trigger a spontaneous form 
of EAE after exposure to myelin oligodendrocytes glycoprotein (MOG) (168). 
Interestingly, studies also found that the microbiome influences the development of the 
BBB, as germ-free mice had disrupted formation of this important barrier protecting the 
host CNS (169). Among the factors related to the microbiome which influence the host 
immune system response, short chain fatty acids (SCFAs) are some of the most 
significant functioning metabolites synthesized by the gut microbiome. SCFAs were 
found to be critical modulators in the gastrointestinal tract capable of regulating the pro-
inflammatory Th1/Th17 and anti-inflammatory Treg responses during autoimmune 
neuroinflammation (170). 
 In the current study, we investigated the use of combination cannabinoid 
treatment (THC+CBD) during EAE to determine how this treatment effects the gut 
microbiome and whether these alterations influenced THC+CBD-mediated protective 
effects. The results showed THC+CBD treatment of EAE results in reduction in disease 
severity and alterations in the pro-inflammatory immune response. 16S rRNA sequencing 
of colon contents revealed THC+CBD treatment altered the gut microbiome during EAE, 
particularly by reducing the abundance of Akkermansia muciniphila (A.muc) which was 
increased during the disease state. In addition to the alterations in the microbial 
phylogenetic profile, THC+CBD treatment during EAE resulted in changes in the gut 
metabolome, specifically leading to increases in SCFAs such as anti-inflammatory 
butyrate. Lastly, fecal transfer experiments revealed that the protective effects of 
THC+CBD during EAE was at least partly due to the alterations of the microbiome 





3.3 MATERIAL AND METHODS 
Mice  
 6-8-week-old female C57BL/6 mice were purchased from the Jackson 
laboratories (Bar Harbor, ME). Mice were housed in the Animal Resource Facility (ARF) 
at the University of South Carolina, School of Medicine. All animal experiments were 
performed in accordance with National Institutes of Health (NIH) guidelines under 
protocols approved by the Institutional Animal Care and Use Committee (IACUC) of the 
University of South Carolina. 
Reagents 
 The following reagents were used during the experiments and purchased as 
follows: THC and CBD were from Cayman Chemical (Ann Arbor, MI); red blood cell 
(RBC) lysis buffer and β-mercaptoethanol were from Sigma-Aldrich (St. Louis, MO); 
percoll was purchased from GE Healthcare Life Sciences (Pittsburgh, PA); RPMI 
1640, l-glutamine, HEPES, phosphate-buffered saline, and fetal bovine serum (FBS) 
were from VWR (West Chester, PA); myelin oligodendrocyte glycoprotein (MOG35-55) 
peptide and H-MEVGWYRSPFSRVVHLYRNGK-OH were from PolyPeptide 
Laboratories (San Diego, CA); Mycobacterium tuberculosis (strain H37Ra) and complete 
Freund’s adjuvant were purchased from Difco (Detroit, MI); pertussis toxin was 
purchased from List Biological Laboratories (Campbell, CA); Neural Tissue Dissociation 
Kit (P) was purchased from Miltenyi Biotech Inc. (Auburn, CA); QIAamp DNA Stool 
mini kit was purchased from Qiagen (Germantown, MD); Illumina MiSeq reagents were 
purchased from Illumina, Inc. (San Diego, CA) except The Agencourt AMPure XP 





Lipopolysaccharide (LPS) ELISA Kit (Sandwich ELISA) was purchased from LifeSpan 
Biosciences, Inc. (Seattle, WA. USA). Besides, the following mouse-specific ELISA kits 
were purchased from BioLegend (San Diego, CA): IL-10, IL-17A, IFN-, and TGF-.  
EAE induction and treatment with THC+CBD  
 To investigate the effect of the THC+CBD combination, EAE was induced as 
described previously (104, 105). Briefly, mice were given a subcutaneous injection with 
100 μl of 150 μg MOG35-55 peptide emulsified in complete Freund’s adjuvant 
containing 8 mg/ml killed Mycobacterium tuberculosis (strain H37Ra), followed by an 
intraperitoneal injection (i.p.) of 200 ng of pertussis toxin on day 0. These injections were 
repeated with 400 ng pertussis toxin on day 2. For treatment, EAE mice were randomized 
and treated with an i.p. injection of 10 mg/kg THC+CBD or vehicle (2% 
dimethylsulfoxide, DMSO; 20% ethanol diluted in PBS) on day 10 after the induction of 
EAE, and this treatment regimen continued once daily until the end of the experiment. 
Animals were monitored, and clinical scores were observed and evaluated daily.  
EAE clinical scoring 
 The measured parameters for clinical EAE scores were recorded as follow: 0 = 
normal; 1 = partial loss of tail tonicity/inability to curl the distal end of the tail; 2 = tail 
atony/ moderately clumsy/impaired righting; 3 = hind limbs weakness/partial paralysis; 4 
= complete hind limp paralysis/fore limb weakness; 5 = tetraplegia/moribund (106). The 
mean score was calculated for each group every day. Proper care of paralytic animals 
unable to access food and water was ensured by providing supplementary DietGel Boost 
and Hydrogel from Daily H2O (Portland, ME) on a daily basis. Death was not used as an 





with an overdose anesthetic isoflurane (%5), a method approved by the American 
Association for Laboratory Animal Science and university IACUC. 
Histopathological analysis  
 For histopathological evaluation, brain tissues from experimental mice were 
isolated at day 15 after EAE induction during the peak of disease. Prior to brain isolation, 
euthanized mice were perfused with 10 mL heparinized PBS to flush out vascular 
circulating cells. Isolated brain tissues obtained after perfusion were immersed in 4% 
paraformaldehyde (PFA) overnight prior to embedding in paraffin. Microtome sections 
(7 μm) were obtained, and tissue sections were stained with Hematoxylin and Eosin 
(H&E) to evaluate damage and cellular infiltration into the CNS. 
Analysis of cytokine production 
 Pro-inflammatory (IFNγ and IL17A) and anti-inflammatory (IL-10 and 
transforming growth factor-, TGF-) cytokines were evaluated in the serum and ex vivo 
splenocyte supernatants from experimental groups using ELISA kits as previously 
described (104). For serum, blood was collected on day 15 and serum was separated and 
stored at -80°C until analysis. For evaluation of the peripheral response in the spleen 
during EAE, spleens from experimental mice were excised at the end of the experiment 
and processed into a cell single suspension. Isolated splenocytes were seeded (1x106 
cells/ml) cultured for 24 hours at 37°C and 5% CO2 overnight in complete RPMI 1640 
media supplemented with 10% fetal bovine serum, 10 mM l-glutamine, 10 mM HEPES, 
50 μM β-mercaptoethanol, and 100 μg/ml penicillin/streptomycin. After 24 hours, cell 






Flow cytometry analysis for myeloid-derived suppressor cells (MDSCs) 
 To determine peripheral MDSC induction, spleens were excised prior to perfusion 
in experimental mice. Whole splenocyte tissues were homogenized into a single cell 
suspension and subjected to red blood cell (RBS) lysis. Cells suspensions from 
experimental groups were tagged with fluorescently-labeled monoclonal antibodies 
(mAbs) purchased from Biolegend. Specifically, PE-labeled Gr-1 and AlexaFluro700-
labeled CD11b were used to identify MDSC populations in the spleen. Antibody-tagged 
samples were run a BD FACs Celesta flow cytometer and analyzed using FlowJo 
software from BD Biosciences (San Jose, CA). 
Bacterial phylogenetic and metabolomic profiling by 16S rRNA analysis 
 16S rRNA sequencing using the Illumina MiSeq platform and analysis with 
Nephele were performed as previously described (171). Briefly, cecal flushes were 
collected from Naïve, EAE-VEH and EAE-(THC+CBD) mice under antiseptic 
conditions, and collected samples were kept frozen at - 80 °C until DNA extraction. 
Isolation of DNA from stool was performed using the QIAamp DNA Stool Mini Kit from 
Qiagen as per the instructions from the manufacturer. 200 mg of cecal contents was 
collected per experimental mouse. Sequencing was performed on the Illumina MiSeq 
platform to generate reads, and all further downstream analysis was performed using the 
Nephele platform from the National Institute of Allergy and Infectious Diseases (NIAID) 
Office of Cyber Infrastructure and Computational Biology (OCICB) in Bethesda, MD 
(172). To analyze phylogenetic and possible metabolomic alterations within samples, 
Nephele-based analysis using the Phylogenetic Investigation of Communities by 





reference against the Greengenes database (Greengene_99) at taxa levels 2 and 3 
(Phylum and Class) for KEGG annotations. In order to determine significantly altered 
bacteria and processes within the samples, linear discrimination analysis of effect size 
(LefSE) was performed operational taxonomic unit (OTU) tables generated from Nephele 
(173). To validate A.muc (F 5GACTAGAGTAATGGAGGGGGAA 3  R 
 5GTATCTAATCCCTTTCGCTCCC 3) expression, PCR was performed using Qiagen 
miScript cDNA synthesis kit and Biorad SSO advanced SYBR Green PCR reagents for 
analysis on a CFX96 qPCR system. Fold change of A.muc was determined using the 
delta-delta-CT method expressed relatively to a Eubacteria (Forward: 
5ACTCCTACGGGAGGCAGCAGT; 3 Reverse: 5ATTACCGCGGCTGCTGGC 3) 
control. 
Quantification of SCFAs  
 Quantification of SCFAs was performed as previously described (166, 171). 
Briefly, 100mg of cecal contents was weighted and suspended in dIH2O to a final 
concentration of 250 mg/mL. Samples were vortexed until completely homogenized, then 
acidified with 1:4 volumes of 25% metaphosphoric acid. Acidified samples were 
vortexed and placed on ice for 30 min. Cold acidified samples were centrifuged at 
12,000xg for 15 minutes at 4°C. Supernatants were filtered over ultra-free MC columns 
(0.22 um GVDurapore, UFC30GV0S, ThermoFisher Scientific) and centrifuge at 
12,000xg for 4 minutes at 4°C. Samples were stored until later downstream quantification 
at -80°C. To quantify SCFAs and determine their concentrations within experimental 
samples, standards were prepared as shown in Table 1. Ethylbutyric acid (0.10 mM) was 





samples were thawed and 100L was transferred to a new microfuge tube, along with 
100L of the standards. For the IS-blank, 100L ddH2O was transferred to a new 
microcentrifuge tube. Then, 60L of 0.1mM IS was added to each sample, standard, and 
IS-blank for a final volume of 160 L. Two sets of glass GC vials (Supelco 29056-U) 
were labeled for each sample, standard, and IS-blank.  Approximately 400L of 
methyl tert-butyl ether (MTBE) was added to one set of glass vials using a 2mL glass 
serological pipette. Samples, standards, and IS-blank from the tubes that had final volume 
of 160L(100L ddH2O+60L of 0.1mM IS) were added into the glass vials containing 
MTBE. Samples were vortexed ~5-10 seconds, then spun down at 1.300 rpm for 5 
minutes at room temperature. Lastly, 100L of the top organic layer from the samples 
was placed into the other set of glass vials for analysis. Samples were stored at -20°C 
until analyzed with the gas chromatography flame-ionized detection (GC-FID) 
instrument (174). 
Lipopolysaccharide (LPS) Detection in brain lysates      
 Brain tissues were collected from naïve, EAE-VEH and EAE-(THC+CBD), 
rinsed with 1X PBS, and minced into a single cell suspension. Cells were collected and 
pelleted by centrifugation, and the supernatant was removed. Cells were washed 3 times 
with 1X cold-PBS and suspended in 1X PBS to be lysed by freezing the cells at -20°C 
and allowing to thaw at room temperature 3 times. Cells were centrifuged at 1500×g for 
10 minutes at 4°C to remove cellular debris. The collected cell supernatants were 
analyzed for detection of LPS by using a LPS ELISA Kit (Sandwich ELISA) for 






Fecal microbial transplantation (FMT)  
 In order to perform FMT experiments, the EAE model was induced as described 
above. Cecal flushes from experimental groups, Naïve, EAE-VEH, and EAE-
(THC+CBD), were harvested aseptically at the peak of the disease (day 15) using an 
anaerobic chamber were suspended in sterile PBS containing 30% glycerol for storage at 
-80C until used. To prepare mice for FMTs, 6-week-old C57Bl/6J mice we administered 
antibiotics (streptomycin 1g/L and ampicillin 1g/L, referred to as “Abx”) by oral gavage 
(100μL) daily for 4 weeks. Abx-treated mice were kept in autoclaved cages with 
autoclaved water and chow. To ensure depletion of the microbiome, PCR validation 
(DNA collected from stool) using a primer for Eubacteria (Forward: 
5ACTCCTACGGGAGGCAGCAGT; 3 Reverse: 5ATTACCGCGGCTGCTGGC 3) 
and bacterial culture plates were performed. EAE was induced in mice treated with Abx 
for 4 weeks and after symptoms started, mice were randomized into 4 groups: FMT 
EAE+Control (PBS only), FMT EAE+Naive, FMT EAE+VEH, FMT 
EAE+(THC+CBD). We performed daily FMTs (50mg) by oral gavage starting at day 10 
until the end of the experiment (day 18). 
Statistics 
 We performed our statistical analysis using GraphPad Prism 6 (GraphPad Inc, La 
Jolla, CA). The data shown in this study represents at least three independent experiments 
unless otherwise stated. Average values ± standard error mean (SEM) are shown for 
experiments to determine to significance. The statistical differences between two 
experimental groups were calculated using ANOVA and student t test. For comparisons 





test were performed. EAE clinical scores over a period of time were evaluated using 
groups of at least five mice and significance was determined using two-way ANOVA and 
Tukey’s multiple comparisons test in order to determine significance during each 
individual time point (e.g. days). A P value <0.05 was considered significant for all 
experiments. 
3.4 RESULTS  
Combination THC+CBD treatment reduces EAE disease and promotes anti-
inflammatory response 
 
 In order to determine the effectiveness of THC+CBD treatment in the EAE 
model, disease induction and treatment were performed as outlined in Figure 1A, initially 
comparing the following groups: EAE mice treated with vehicle (EAE-VEH) and EAE 
mice treated with cannabinoid combination (EAE-(THC+CBD)). Clinical EAE scores 
showed EAE-(THC+CBD) had reduced disease severity when compared to EAE-VEH 
disease controls (Figure 1B). Histological results from the brains taken at day 15 of the 
experimental model revealed that as expected, when compared to naïve wild-type (WT) 
mice, EAE-VEH mice had high number of infiltrating cells and signs of tissue damage, 
however, EAE-(THC+CBD) brain tissues showed similar naïve group morphology 
(Figure 1C). Serum samples also showed EAE-(THC+CBD) mice had a decrease in the 
pro-inflammatory cytokines levels for IL-17A (Figure 1D) and IFN- (Figure 1E) when 
compared to the disease controls. However, EAE-(THC+CBD) serum had increases in 
the levels of anti-inflammatory cytokines TGF- (Figure 1F) and IL-10 (Figure 1G) 
compared to EAE-VEH groups. In the periphery, splenic levels of pro-inflammatory 
cytokines IL-17A (Figure 1H) and IFN- (Figure 1I) were also reduced with THC+CBD 





suppressor cells (MDSCs) when compared to disease controls. Collectively, this data 
showed that THC+CBD treatment was able to reduce EAE disease severity and promote 
and anti-inflammatory response.   
Combination THC+CBD treatment alters the gut microbiome during EAE 
induction 
 
 16S rRNA gene sequencing was performed on cecal flushes from the following 
groups: Naïve, EAE-VEH, and EAE-(THC+CBD). The Illumina MiSeq platform using 
primers targeting the V3 and V4 variable regions was used. Sequences were translated by 
using the 16S QIIME Paired-End pipeline implemented in Nephele platform (release 1.6 
which uses QIIME 1.9.1) (175). OTUs were picked with QIIME’s unclust-based (176), 
open-reference OTU picking protocol (177), and the taxonomic assignment was done 
against Greengenes-99 reference sequence set at 99% similarity, as previously described 
(178). Alpha diversity, as assessed using Chao1 rarefraction measure, showed that EAE-
induced mice had slightly lower abundances of bacteria in the gut (Figure 2A). Beta 
diversity, depicted in a 3D principle coordinate analysis (PCOA) plot, showed that three 
experimental groups clustered together well within their own groups, suggesting there 
was divergence in the gut microbiome population (Figure 2B). At the phylum level 
(Figure 2C), there were notable differences in the taxa. EAE-induced mice had 
significantly lower abundances of Bacteriodetes when compared to Naïve mice (Figure 
2D), whereas EAE-treated with THC+CBD had higher levels of Firmicutes when 
compared to the disease controls (Figure 2E). Both EAE groups had a significant drop in 
Tenericutes when compared to the controls (Figure 2F), but had increased abundance of 
Verrucomicrobia, although EAE-(THC+CBD) had reduced levels compared to EAE-





mice compared to controls, but the abundance of this phylum was reduced to normal 
levels after treatment with THC+CBD (Figure 2H). Significant alterations in the gut 
microbiome were observed throughout the various taxa levels from class to genus among 
the experimental groups with an interesting consistent trend showing EAE-associated 
increase in Verrucomicrobia sub-levels was decreased after THC+CBD treatment 
(Supplementary Figures 1-4).  
 In order to ascertain the most significantly altered bacteria between naïve and 
disease controls and identify any potential microbial biomarkers of disease, LefSE was 
performed on the OTU output data (Figure 3A). When examining microbial disruption 
between the Naïve and EAE-VEH groups, the bacterial species Akkermansia 
muciniphilia (A.muc) within the Verrucomicrobiae class had the highest LDA score in 
EAE-induced mice (Figure 3B). When considering the levels in treated groups, EAE-
(THC+CBD) mice had significantly reduced levels of this EAE-associated bacteria 
(Figure 3C). The sequencing data was validated using primers specific for A.muc, 
reinforcing the observation that THC+CBD treatment reduced the levels of this bacteria 
that were significantly higher in EAE mice when compared to naïve controls (Figure 3D). 
Treatment with THC+CBD during EAE alters gut bacterial metabolite production 
 In addition to the phylogenetic data from 16s rRNA sequencing, in silico 
computational metabolomics was performed using the PICRUSt method. LefSE analysis 
of the output data showed that when comparing disease controls (EAE-VEH) to EAE-
(THC+CBD) treated groups, several KEGG pathways had high LDA scores in the 
disease state (Figure 4A). For example, LPS biosynthesis, a key component in gram-





naïve mice, but this was greatly reduced after treatment with THC+CBD (Figure 4B). In 
order to corroborate this in silico data, brain lysates from experimental groups were 
analyzed for detection of LPS levels. When comparing all the experimental groups, 
lysates from the brains of EAE-VEH mice had significantly higher levels of LPS 
compared to controls, however, EAE-(THC+CBD) mice reduced this level significantly 
(Figure 4C). Production of known SCFAs was also evaluated from cecal flushes. 
Compared to Naïve controls, EAE-induced mice (untreated or untreated) had higher 
levels of acetic (Figure 4D) and propionic acids (Figure 4E), though only EAE-
(THC+CBD) mice appeared to have increased isobutyric acid (Figure 4F). In addition, 
EAE-(THC+CBD) samples had significantly higher levels of butyric (Figure 4G), 
isovaleric (Figure 4H), and valeric (Figure 4I) acids compared to naïve or disease 
controls. Collectively, data showed EAE-(THC+CBD) mice had global increases in 
SCFA production, in addition to altering other bacterial metabolomic pathways such as 
LPS production. 
FMT of THC+CDB-altered microbiome attenuates EAE disease severity 
 In order to determine if the alterations in the microbiome by THC+CBD treatment 
mediated any protective effects against EAE induction, FMT experiments were 
performed as described in Figure 5A. To deplete the microbiome, mice were treated with 
Abx for 4 weeks, and confirmation of this depletion was confirmed with PCR (Figure 
5B) and bacterial culturing (Figure 5C). For FMTs, EAE-induced mice were fed either 
controls (FMT EAE Control), or fecal material from Naïve (FMT EAE-Naïve), disease 
controls (FMT EAE-VEH), or disease mice treated with THC+CBD (FMT EAE-





with Abx had reduced disease severity compared to normal EAE experiments (Figure 
5D), more than likely due to the dependency of EAE induction on the microbiota. 
However, FMT EAE-(THC+CBD) mice had significantly reduced scores compared to 
the other groups. This data confirms that alterations in the microbiome by combination 
THC+CBD leads to protection against EAE-induction, thus providing another interesting 
mechanism by when cannabinoids are capable of protecting against inflammatory 
diseases. 
3.5 DISCUSSION 
 MS is a neurological autoimmune disease caused by a combination of genetic and 
environmental exposures which has increased in incidence in the past several decades 
suggesting a changes in environmental risk factors (179), and gut microbiota might be 
one of these environmental factors (50). Our study demonstrated a mixture of 
cannabinoids (THC and CBD) in EAE resulted in alleviation of the clinical symptoms. A 
previous report from our lab also found that treatment with CBD alone was able to 
attenuate EAE-induced disease (16). Such findings were observed even 20 years ago 
when it was reported that a MS patient who smoked marijuana had decreased incident of 
MS-associated ataxia and spasticity (180), and since then several reports have shown 
cannabinoids are effective at lessening MS disease burden (181, 182). There is even a 
oromucosal pharmaceutical cannabinoid spray (Sativex) available to reduce spasticity 
and pain attributed to MS (183). In fact, there is a reported increase in use of cannabis by 
MS patients in the United States (184). Such an increase in use is not surprising given the 





 Several mechanisms have been attributed to the beneficial effects of cannabinoids 
like THC and CBD, to include those that affect the immune system. In the current report, 
treatment with THC+CBD resulted in reduction of pro-inflammatory cytokines 
production and increase in anti-inflammatory cytokines production. In early reports, 
Kozela et al found that CBD was found to suppress microglial activity and prevent T cell 
proliferation associated with inducible EAE (185). The same research group later 
reported that separately THC and CBD were able to suppress Th17 cells and 
proinflammatory cytokines such as TNFα and IFNγ during EAE (19), consistent with our 
combination treatment findings. In addition to suppressing the pro-inflammatory 
phenotype, our lab has also shown that cannabinoids are able to increase abundance and 
activity of anti-inflammatory immune cell phenotypes, such as Tregs and MDSCs, in 
various inflammatory models of disease (16, 18, 22, 121, 159, 186).  Therapeutic agents 
that can reduce pro-inflammatory Th1/Th17 subsets and increase anti-inflammatory 
Th2/Treg/MDSC subsets can potential help patients suffering from MS, reinforcing the 
case that these cannabinoids are a good source of alternative therapy for the patient 
population. Despite a continuing field of research in cannabinoids and MS, few have yet 
to study another possible mechanism linked to the disease, which consists of examining 
the effects occurring in the microbiome.  
 Current research has noted that MS is characterized by alterations in amount, 
composition, and metabolomic profile of the microbiome (187). Of particularly note in 
this study was during EAE induction and treatment significant changes were observed in 
A. Muc which is reported to be involved in exacerbation of both the human MS patients 





A. Muc in MS patients was capable of increasing the severity of EAE when transplanted 
into mice (189). In a study done by Jangi et al., researchers found that the genus 
Akkermansia increased in patients with MS (50). In another study, researchers found that 
untreated MS subjects showed increase of Akkermansia as well (190). The current report 
suggests that cannabinoid treatment may be able to regulate A. Muc, which is certainly 
possible given that blocking cannabinoid receptors lead to a significant increase in A. 
Muc in an model of obesity (161). Interestingly, use of another natural product 
(resveratrol) was found to regulate the endocannabinoid system to decrease A. Muc in 
high-fat diet-induced non-alcoholic steatohepatitis (191).  
 Microbial dysbiosis in MS/EAE hosts characterized by increased gram-negative 
bacteria, such as A.Muc, could be linked to increased LPS, which was observed in brain 
lysates from EAE mice in the current study. Elevated LPS levels suggest a shift to 
increased presence of gram negative bacterial endotoxin and a study has shown LPS 
results in degeneration of myelin and results in white matter damage (192). This makes 
sense as LPS is linked to a proinflammatory response in the host capable of activating 
microglia, disrupting the BBB, and making Tregs act in a defective manner (193). In 
addition, the current study shows THC+CBD treatment results in widespread increases in 
SCFAs. SCFAs play a very important role in regulating the inflammatory response and 
preventing autoimmune diseases such as MS by suppressing the production of Th17 cells 
and promoting the production of Treg cells from CD4 naïve T cells (194). In fact, a 
recent report showed that gut dysbiosis and lack of SCFAs were present in Chinese MS 
patients (195). The results of all these aforementioned studies, combined with the results 





the future treatment of MS patients, by way of altering the gut microbiome and 





Figure 3.1 Combination THC+CBD treatment attenuates EAE disease severity 
and promotes anti-inflammatory immune response. (A) Experimental design of 
EAE experiments using combined treatment of THC+CBD (10mg/kg). (B) Clinical 
scores, outlined in the Materials and Methods section, of EAE mice treated with 
VEH (n = 10) or THC+CBD (n = 10). Significance was determined using two-way 
ANOVA and Tukey’s multiple comparisons test to evaluate significance at each day. 
Significant p values (*P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001) are 
indicated below respective days after EAE induction. (C) Representative images of 
brain histopathology stained with H&E (10×) at day 15 from experimental groups: 
Naïve, EAE+VEH, and EAE+THC; scale bars, 100 µM. (D-G) Serum was collected 
at the peak of the disease (day 15) to determine levels of IL-17A (D), IFN-γ (E), 
TGF-β (F), and IL-10 (G). (H-I) Supernatants from cultured splenocytes were 
collected after 24hrs to analyze IL-17A (H) and IFN-γ (I) by ELISA. (J-K) 
Representative flow cytometry plots (J) to determine MDSC (Gr-1+CD11b+) 
percentages (K). Bar graph data are expressed as the mean ± SEM and statistical 
significance is indicated as *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001 





Figure 3.2 Combination THC+CBD treatment alters the gut microbiome during 
EAE disease. (A-B) 16S rRNA sequencing from the cecal flushes was performed on 
Naive (n=4), EAE-VEH (n=5), and EAE-(THC+CBD) (n=6) experimental mice and 
data are representative of one experiment. Sequenced reads were analyzed using 
Nephele to generate chao1 alpha diversity (A) and beta diversity PCOA (B) plots. (C) 
Depicted stacked bar graphs of percent OTUs at the phylum level. (D-H) Individual 
bar graphs are depicted for the following phylum level: Bacteriodetes (D), Firmicutes 
(E), Tenericutes (F), Verrucomicrobia (G), and Proteobacteria (H). Bar graph data are 
expressed as the mean ± SEM and statistical significance is indicated as *P < 0.05, 
**P < 0.01, ***P < 0.001 and ****P < 0.0001. Significance was determined using 







Figure 3.3  LefSE analysis identifies A.Muc as a potential biomarker of EAE disease 
which is reduced after THC+CBD treatment. (A-B) 16S rRNA sequencing from the 
cecal flushes was performed on Naive (n=4), EAE-VEH (n=5), and EAE-(THC+CBD) 
(n=6) experimental mice and OTU data was subjected to LefSE analysis to generate 
cladogram (A) and LDA scores (B) between Naïve and EAE-VEH groups. For LefSe 
data, the alpha factorial Kruskal-Wallis test among classes was set to 0.05, and the 
threshold on the logarithmic LDA score for discriminative features was set at3. (C) Bar 
graph depicting the percent OTUs of A.Muc generated from 16S rRNA sequencing in 
Naïve, EAE-VEH, and EAE-(THC+CBD) groups. (D) Bar graph depicting PCR 
validation and fold change of A.Muc in Naïve (n=5), EAE-VEH (n=5), and EAE-
(THC+CBD) (n=5) groups. Bar graph data are expressed as the mean ± SEM and 
statistical significance is indicated as *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 







Figure 3.4 Combination THC+CBD treatment alters the gut microbiome 
metabolome during EAE disease. (A) LDA scores between EAE-VEH and EAE-
(THC+CBD) groups using PICRUSt-generated Level 3 (L3) KEGG pathways of 16S 
rRNA sequencing data from Naive (n=4), EAE-VEH (n=5), and EAE-(THC+CBD) (n=6) 
experimental mice. (B) Individual bar graph depicting percent OTUs attributed to LPS 
biosynthesis from Naive (n=4), EAE-VEH (n=5), and EAE-(THC+CBD) (n=6) 
experimental mice after PICRUSt analysis. (C) Concentration of LPS levels from 
cultured brain lysates detected by ELISA for Naive (n=5), EAE-VEH (n=5), and EAE-
(THC+CBD) (n=5) samples. (D-I) Concentrations of SCFAs from cecal flushes of Naive 
(n=5), EAE-VEH (n=5), and EAE-(THC+CBD) (n=5) samples. Bar graph data are 
expressed as the mean ± SEM and statistical significance is indicated as *P < 0.05, **P < 
0.01, ***P < 0.001 and ****P < 0.0001. Significance was determined using one-way 






Figure 3.5 FMT of THC+CBD altered microbiome attenuates EAE severity. (A) 
Experimental design of FMT EAE experiments where 4-week Abx-treated mice received 
FMTs (50mg) from either Control PBS (n=3), Naïve (n=3), EAE-VEH (n=5), or EAE-
(THC+CBD) (n=5) mice. (B) PCR validation confirming Abx mice had depleted 
microbiome. Depicted is the fold change of Eubacteria normalized to 18S compared 
between WT(n=5) and WT+Abx (n=5). Bar graph data are expressed as the mean ± SEM 
and statistical significance is indicated as *P < 0.05, **P < 0.01, ***P < 0.001 and ****P 
< 0.0001 (C) Representative feces cultured plates from WT (n=4) and WT+Abx (n=4) 
mice to confirm depletion of microbiome. (D) Clinical scores, outlined in the Materials 
and Methods section, of FMT EAE mice treated with Control PBS (n=3), Naïve (n=3), 
EAE-VEH (n=5), or EAE-(THC+CBD) (n=5) fecal material. Significance was 
determined using two-way ANOVA and Tukey’s multiple comparisons test to evaluate 
significance at each day. Significant p values (*P < 0.05, **P < 0.01, ***P < 0.001 and 






Figure 3.6 16S rRNA analysis of EAE treated with THC+CBD at the class level. (A-
B) Induction of EAE and treatment with THC+CBD, followed by Nephele 16S rRNA 
analysis was performed as described in Figure 2 legend and Materials and Methods for 
Naïve (n=4), EAE+VEH (n=5), and EAE+(THC+CBD) (n=6) experimental groups. (A) 
Depicted are stacked bar graphs for percent OTUs at the class level. (B) Significantly 
altered bacteria at the class level depicted as bar graphs. Bar graph data are expressed as 
the mean ± SEM and statistical significance is indicated as *P < 0.05, **P < 0.01, ***P < 
0.001 and ****P < 0.0001. Significance was determined using one-way ANOVA and 







Figure 3.7 16S rRNA analysis of EAE treated with THC+CBD at the order level. (A-
B). Induction of EAE and treatment with THC+CBD, followed by Nephele 16S rRNA 
analysis was performed as described in Figure 2 legend and Materials and Methods for 
Naïve (n=4), EAE+VEH (n=5), and EAE+(THC+CBD) (n=6) experimental groups. (A) 
Depicted are stacked bar graphs for percent OTUs at the order level. (B) Significantly 
altered bacteria at the order level depicted as bar graphs. Bar graph data are expressed as 
the mean ± SEM and statistical significance is indicated as *P < 0.05, **P < 0.01, ***P < 
0.001 and ****P < 0.0001. Significance was determined using one-way ANOVA and 







 Figure 3.8 16S rRNA analysis of EAE treated with THC+CBD at the family level. 
(A-B). Induction of EAE and treatment with THC+CBD, followed by Nephele 16S 
rRNA analysis was performed as described in Figure 2 legend and Materials and 
Methods for Naïve (n=4), EAE+VEH (n=5), and EAE+(THC+CBD) (n=6) experimental 
groups. (A) Depicted are stacked bar graphs for percent OTUs at the family level. (B) 
Significantly altered bacteria at the family level depicted as bar graphs. Bar graph data 
are expressed as the mean ± SEM and statistical significance is indicated as *P < 0.05, 
**P < 0.01, ***P < 0.001 and ****P < 0.0001. Significance was determined using one-







Figure 3.9 16S rRNA analysis of EAE treated with THC+CBD at the genus level. 
(A-B) Induction of EAE and treatment with THC+CBD, followed by Nephele 16S rRNA 
analysis was performed as described in Figure 2 legend and Materials and Methods for 
Naïve (n=4), EAE+VEH (n=5), and EAE+(THC+CBD) (n=6) experimental groups. (A) 
Depicted are stacked bar graphs for percent OTUs at the genus level. (B) Significantly 
altered bacteria at the genus level depicted as bar graphs. Bar graph data are expressed as 
the mean ± SEM and statistical significance is indicated as *P < 0.05, **P < 0.01, ***P < 
0.001 and ****P < 0.0001. Significance was determined using one-way ANOVA and 
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AHR ACTIVATION BY TCDD (2,3,7,8-TETRACHLORODIBENZO-
P-DIOXIN) ATTENUATES PERTUSSIS TOXIN-INDUCED 
INFLAMMATORY RESPONSES BY DIFFERENTIAL 
REGULATION OF TREGS AND TH17 CELLS THROUGH 
SPECIFIC TARGETING OF MICRORNA
 
4.1 ABSTRACT 
TCDD (2,3,7,8-Tetrachlorodibenzo-p-dioxin), a halogenated aromatic 
hydrocarbon, is an environmental contaminant and potent ligand for Aryl hydrocarbon 
hydroxylase (AhR) ligand. Pertussis Toxin (PTX) is a virulence factor found in 
Bordetella pertussis, a human respiratory pathogen that causes whooping cough. PTX 
promotes colonization and disease promotion by triggering heightened inflammatory 
response.  In the current study, we investigated if AhR activation by TCDD can attenuate 
PTX-mediated systemic inflammation.  To this end, C57BL/6 mice were injected i.p. 
with TCDD (25 g/kg body weight) or vehicle (VEH, corn oil) followed by an i.p. 
injection of PTX (400 ng/mouse) Twenty-four hours later, mice were rechallenged with 
the same dose of PTX and 3 days later, mice were euthanized for immunological studies.   
PTX+VEH group has elevated levels of pro-inflammatory cytokines (IL-17A, IL-6, and 
IFNγ) in serum and increased proportions of CD4+ Th1 and Th17 cells in spleens.  In 
contrast, PTX+TCDD group had significantly lower levels of these inflammatory 
cytokines and decreased proportions of Th1 and Th17 cells but increased proportions of 





also had elevated levels of IL-10, and TFG- , potent anti-inflammatory cytokines.  
microRNAs (miRs) analysis of CD4+ T cells from the spleens of PTX+TCDD treated 
mice revealed significant alterations in their expression and several of these miRs 
targeted cytokines and signaling molecules involved in inflammation.  Specifically, 
PTX+TCDD group had significantly enhanced expression of miR-3082-5p that targeted 
IL-17, and decreased expression of miR-1224-5p, which targeted FoxP3.  Transfection 
studies with these miR mimics and inhibitors confirmed that this was indeed the 
mechanism through which TCDD suppressed Th17 while inducing Tregs.  Together, the 
current study demonstrates that AhR activation by TCDD suppresses PTX-induced 
inflammation through miR regulation that trigger reciprocal differentiation of Tregs and 
Th17 cells.  These studies also suggest that AhR activation may serve as a treatment 
modality to suppress heightened inflammation induced during B. pertussis infection. 
4.2 INTRODUCTION 
TCDD (2,3,7,8-Tetrachlorodibenzo-p-dioxin), also known as dioxin, is one of the 
polyhalogenated aromatic hydrocarbons compounds (196). TCDD is a potent agonist 
with high binding affinity to aryl hydrocarbon receptor (AhR) because which it is 
extensively used to study the impact of AhR activation on various physiological and 
immune functions (197, 198). AhR is a basic helix-loop-helix/PAS transcription factor 
localized in the cytoplasm. More recent studies have shown that AhR activation can 
not only cause toxicity but also regulate the immune response, specifically the 
regulation of T cell differentiation (199, 200) Activation of AhR by TCDD or other 
ligands leads to translocation to the nucleus where it binds to its dimerization partner, 





initiates transcription of genes with promoters containing a dioxin-responsive element 
(DRE) consensus sequence.(201, 202)  In addition to the well characterized ligand, 
TCDD, a variety of other compounds including tryptophan derivatives, dietary flavonoids 
and biphenyls have been shown to bind to AhR with varying affinities (203).  While AhR 
was initially discovered in the context of activation by environmental chemicals leading 
to induction of xenobiotic metabolizing enzymes, and regulating the toxicity mediated by 
such chemicals, more recent studies have shown that AhR activation plays diverse roles 
in cellular functions, especially in the regulation of T cell differentiation (204). 
Pertussis Toxin (PTX) is one of the most important virulence associated factors of 
Bordetella pertussis, the gram-negative bacterium that is responsible of whooping cough. 
PTX belongs to the A-B structure class of bacterial toxins (205). Its B subunit binds to a 
cell surface receptor, and the enzymatically active A subunit interrupts intracellular 
signaling via irreversible ADP ribosylation of the Gi subclass of G protein (206). PTX 
exerts its effects through binding to G protein coupled receptors, and since they are 
present in several mammalian cell types, it affects most cells types (207). One of the Gi/o 
protein dependent effects of PTX is lymphocytosis (208, 209). Moreover, PTX also acts 
via a phosphokinase C pathway to increase the permeability of the blood-brain barrier 
resulting in neurological effects (210). Studies have shown that PTX can trigger the 
development of Th17 cells that promote inflammation (61, 64, 211). Today, PTX is also 
recognized as a major contributor to autoimmune pathogenesis (212). Previous studies 
have reported increased interferon gamma (IFN-γ) secretion by immune cells in response 
to PTX (213), (214), (215). In addition, at the peak of B. pertussis infection, PTX 





(IL-17).  Several studies comparing wild-type and PTX-deficient B. pertussis strains have 
revealed that PTX plays an important role in promoting infection in the respiratory tract, 
through initial phase of immune suppression followed by enhanced inflammation leading 
to lung pathogenesis.  Thus, agents that suppress inflammation induced by PTX may 
serve as treatment modalities.     
MicroRNAs (miRs) are short non-coding single stranded RNAs, about 19-25 
nucleotides long, that negatively regulate the target genes expression at the post 
transcriptional level (216, 217). A connection between microRNAs and different 
diseases, such as inflammatory bowel disease, autoimmune diseases, and cancers, is 
being investigated (216, 218, 219). Recent studies have shown that exposure to chemicals 
can cause alteration in miRNAs and gene expression that lead to different health 
problems and diseases (217, 220). The evidence linking between the environmental 
chemical contaminants like dioxin and miRNAs functions to human diseases is rapidly 
growing (221). However, it is not clear yet how AhR activation by TCDD alters miRNAs 
or the possibility that TCDD-induced miRNAs may control mRNA that regulate 
inflammation.  Some studies have confirmed an association between deregulation of 
miRNAs and exposure to environmental chemicals and the dioxins are among them 
(222). It has been found that the toxic effects of TCDD may also be controlled by certain 
epigenetic mechanisms like DNA methylation or histones modification (223). The 
involvement of PTX in miRNAs dysregulation is also not fully understood and studies in 
this field still limited. Ge et al. 2013, indicating that miR-202, 342-5p, 206, 487b, 576-5p 
were upregulated and linked to the pathogenesis of inflammatory diseases and 





In this study, we investigated whether AhR activation by TCDD can attenuate 
PTX-induced inflammation in mice and if so, whether such anti-inflammatory action is 
mediated by miRNA.  Our studies demonstrate that TCDD does alter the expression of 
several miRNA that target various cytokine and transcription factors in T cells leading to 
suppression of PTX-mediated inflammation.   
4.3 MATERIALS AND METHODS  
 Mice 
Female C57BL/6 mice (6–8 weeks old) were purchased from Jackson 
Laboratories (Indianapolis, Indiana). Animals were housed in AALAC approved animal 
facility at the School of Medicine, University of South Carolina. Use of mice for 
experiments and their maintenance were approved by the University of South Carolina 
Institutional Animal Care and Use Committee. 
Ethical statement 
Animals used in the experiments of this study were approved by Institutional 
Animal Use and Care committee of University of South Carolina. 
 PTX and TCDD Administration  
TCDD was kindly provided by Dr. Steve Safe (Institute of Biosciences & 
Technology, Texas A&M Health Sciences Center, College Station, Texas). TCDD 
dissolved in DMSO (Sigma, St. Louis, MO) City, State?) was further diluted with corn 
oil (CO), (Sigma. St. Louis, MO) before administration (212). The mice were first 
injected intraperitoneal (ip) with vehicle (CO) or TCDD (25 µg/kg body weight)  and 





Campbell, CA) Twenty-four hours later, the mice were rechallenged with the same dose 
of PTX, as described (16).   
Determination of cytokines Expression by performing ELISA 
To examine the expression of pro- and anti-inflammatory cytokines post PTX and 
Vehicle or TCDD treatments, blood was collected from the portal vein of PTX+VEH and 
PTX+TCDD mice. Sera from mice of both groups were either used immediately or stored 
at -20 °C until further use. Cytokines of interest, such as IL-17A, IL-6, IFNγ and IL-10 
were determined by performing ELISA using BioLegend ELISA Max kits (BioLegend, 
San Diego, CA) and following the protocol of the company and as described in detail 
previously by Busbee et al. (226). 
Flow Cytometry Analysis of splenic cells post PTX and TCDD treatments 
We performed flow cytometry to determine various cell types present in spleens 
of mice treated with PTX + Vehicle and PTX+TCDD. In brief, single cell suspensions of 
spleens from both groups were first prepared. The splenic cells were then treated with 
GolgiPlug purchased from BD (BD Biosciences, San Jose, CA) for at least 6 hrs at 37°C 
to enhance cytokine staining. These cells were then stained using PE-conjugated anti-
mouse CD4 (clone GK1.5) for 30 min at 4°C. Next, the cells were washed with cold PBS 
twice and then stained using following Abs: anti-FoxP3, anti-IL-10, anti-TGF-, anti-IL-
17, and anti-IFN- (Biolegend, San Diego, CA). For MDSCs, splenocytes were stained 
with MDSCs fluorescent conjugated antibodies: CD11b and Gr-1. Stained cells were 
analyzed using Beckman Coulter FC500 flow cytometer (Indianapolis, IN, USA) and 
their software or BD FACSCelesta (BD Biosciences, San Jose, CA) and DIVA software 





Investigation of miRNA profile in splenic CD4+ T cells 
To investigate miRNAs profile in CD4+ splenic cells, CD4+ cells were isolated 
from the splenocytes of PTX+VEH and PTX+TCDD groups of mice using the EasySep 
PE Positive Selection Kit (StemCell Technologies, Cambridge, MA) and anti-CD4 mAb 
(Biolegend, San Diego, CA). The isolated CD4 cells were washed with cold PBS and 
then Qiazol Lysis Reagent (Qiagen, Germantown, MD) was added and either used 
immediately for total RNA including miRNA or stored at -80°C for future use. Total 
RNA including miRNAs were extracted using miRNeasy micro kit (Qiagen, 
Germantown, MD) and according to the manufacturer’s instructions. The concentration 
and purity of the extracted RNAs were determined using the NanoDrop 2000 
spectrophotometer (Thermo Scientific, Wilmington, DE). The expression profile of 
miRNAs was determined by performing microRNA Arrays using the Affymetrix miRNA 
array version 4 (JHMI deep sequencing and microarray core) and GeneChip miRNA 3.0-
array platform. miRNAs data were analyzed using Inguinety Pathway Analysis (IPA, 
Qiagen) as describe (227) . In this study, a > 1.5-fold change in miRNAs expression was 
considered positive (228). 
Validation of miRNAs in splenic CD4+ T cells treated with vehicle or TCDD 
Next, we validated several of miRNA that were selected based on their expression 
and corresponding genes expression. For miRNA expression analysis, cDNA synthesis 
was performed from total RNA using miScript II cDNA Synthesis Kit (# 218161, 
Qiagen, Germantown, MD). Two step miRNA qRT-PCR was carried out using 
SsoAdvanced SYBR green Mix (#1725270 Bio-Rad, Hercules, CA) with mouse primers 





(#MS00001610 Qiagen, Germantown, MD), miR-142-3p (# MS00012201 Qiagen, 
Germantown, MD), and miR-211-3p (# MS00024563 Qiagen, Germantown, MD). 
Expression levels for miRNA were normalized to SNORD96A. All PCR experiments 
used a CFX96 Touch Real-Time PCR Detection System (Bio-Rad, Hercules, CA). Fold 
changes were calculated using the 2−ΔΔCT method.  
Validation of miRNAs-specific gene expression in splenic CD4+ T cells treated with 
vehicle or TCDD 
 
Next, we evaluated the expression of target genes (IL-10, TGF-β1, TGFβ2, 
TGFβR3, TGFβR1, GATA3, SMAD2, IL-6, and RORγt), as described (229).  For gene 
expression analysis, cDNAs was generated as described above from total RNA using 
miScript II cDNA synthesis kit. A two-step amplification with a 60° annealing 
temperature for qRT-PCR was carried out using SsoAdvanced SYBR green supermix 
from Bio-Rad with mouse primers for IL-10, TGF-β1, TGFβ2, TGFβR3, TGFβR1, 
GATA3, SMAD2, IL-6, and RORγt customized and ordered from IDT (Coralville,IA). 
All PCR experiments used a CFX96 Touch Real-Time PCR Detection System (Bio-Rad, 
Hercules, CA), and expression levels were normalized to GAPDH mRNA levels. Fold 
changes were calculated using the 2−ΔΔCT method.  
Transfection of splenic cells with miR-1224-5p and miR-3082-5p mimic or inhibitor 
Two miRNAs (miR-3082-5p and miR-1224-5p) were selected based on their 
alignments with mouse IL-17 and FoxP3 genes. For transfection, we used T cells purified 
from naïve splenocytes and maintained for 24 hours in complete RPMI 1640 medium 
supplemented with 10% heat-inactivated fetal bovine serum, 10 mM L-glutamine, 10 
mM HEPES, 50 μM β-mercaptoethanol, and 100 μg/ml penicillin/streptomycin at 37°C 





2x105 cells/well in a 24-well plate. The following day, the cells were transfected with 
scrambled miRNA (Mock) control or mature miR-1224-5p mimic (Qiagen # 
MSY0005460), miR-1224-5p inhibitor (Qiagen # MSY0005460), mature miR-3082-5p 
mimic or miR-3082-5p inhibitor (Qiagen # YI04103580) using HiPerFect transfection 
reagent (Qiagen, Germantown, MD) and following the protocol of the company.   
Quantitative Real-Time PCR (qRT-PCR) to determine the expression of miRNAs 
and target genes  
 
We performed Q-RT-PCR to determine the expression of miRNAs that target 
FoxP3 and IL17 genes respectively. The selection of these two miRNAs was based on 
their alignment with highly conserved regions of their target genes using miRNA.org, 
miRNAWalk, TargetScan software. As described above, cDNA synthesis was performed 
from total RNAs using miScript II cDNA Synthesis Kit (Qiagen # 218161) and Two step 
miRNA QRT-PCR were carried out using SsoAdvanced SYBR green Mix (BioRad 
#1725270) with mouse primers for SNORD96A (Qiagen #MS00033733), miR-3082-5p 
(Qiagen # MS00025102), miR-1224-5p (Qiagen # MS00011074), Expression levels for 
miRNAs were normalized to SNORD96A. All PCR experiments used a CFX96 Touch 
Real-Time PCR Detection System (Bio-Rad. Fold changes were calculated using the 
2−ΔΔCT method.  
Next, we evaluated the expression of target genes (FoxP3 and IL17) by 
performing QRT-PCR as described above.  All qRT-PCRs were performed using a 
CFX96 Touch Real-Time PCR Detection System (Bio-Rad, Hercules, CA), and 
expression levels were normalized to GAPDH mRNA levels. Fold changes were 
calculated using the 2−ΔΔCT method. Specific primers sequences of genes are provided in 





3082-5p and miR-1224-5p and their respective target genes IL17 and FoxP3 in miR-
3082-5p and miR-1224-5p mimic and inhibitor-transfected T cells treated with 
PTX+Vehicle and PTX+TCDD as described above.  
Statistical analysis 
We used GraphPad Prism6 software to perform statistical analyses. The statistical 
analyses were performed using Student’s t-test and/or ANOVA.  p value <0.05 was 
considered significant. 
4.4 RESULTS 
TCDD suppresses PTX-induced inflammation in mice 
In this study, we investigated the effect of AhR activation by TCDD on PTX-
mediated inflammatory response in C57BL/6 mice. To that end, mice received 
PTX+TCDD or PTX+Veh on day 0 and 24 hr later, all mice received a second dose of 
PTX.  On day 4, the mice were euthanized and studied for inflammation (Fig 1A).  First, 
we performed ELISA using sera from PTX+VEH and PTX+TCDD groups. The data 
showed significant decrease in pro-inflammatory cytokines IL-17A, IFN-γ, and IL-6 in 
PTX+TCDD mice, when compared to PTX+VEH mice (Figure 1B-D). In contrast, there 
was significant increase in IL-10, an anti-inflammatory cytokine in PTX+TCDD group, 
when compared to PTX+VEH group (Figure 1E). These data demonstrated that TCDD 
may suppress pro-inflammatory cytokine response by upregulating the generation of anti-
inflammatory cytokine, IL-10.    
TCDD promotes differential regulation of Tregs and Th17 cells and generation of 
MDSCs in vivo 
 
Next, we investigated the phenotypic changes in spleens harvested from 





CD4+FoxP3+, Th17: CD4+IL17+, Th1: CD4+IFNγ+, and Th2:CD4+IL10+ and 
CD4+TGFβ+ cells.  When we compared Th1 vs Th2 cells, we noted that the percentages 
of Th2 cells (CD4+IL10+ cells and CD4+TGFβ+) were significantly increased in 
PTX+TCDD group, when compared to PTX+VEH group (Figure 2A, B).  In contrast, the 
proportions of Th1 cells was significantly decreased in PTX+TCDD group when 
compared to controls (Figure 2 C). Th17 and Tregs are reciprocally regulated and thus 
when we analyzed these cells in the two groups and found that the percentages of Th17 
cells (CD4+IL17+) were increased while that of Tregs (CD4+FoxP3+) were decreased in 
PTX+VEH group and interestingly, this pattern was completely reversed in PTX+TCDD 
group (Figure 3 A, B).    
We also examined myeloid-derived suppressor cells (MDSCs; CD11b+/Gr1+) in 
spleens of PTX+VEH and PTX+TCDD groups of mice because these cells are also 
highly immunosuppressive and have been known to induce Tregs (230), (231).  There 
was significant increase in both the percentage and numbers of MDSCs in the mice 
exposed to PTX+TCDD group when compared to controls (Figure 4A-C).  
TCDD dysregulates expression of miRNAs in splenic cells in vivo 
To understand anti-inflammatory/immunosuppressive effects of TCDD, we 
investigated the molecular mechanisms that TCDD may regulate to affect gene 
expression. To this end, we performed miRNA arrays using total RNA from splenic 
CD4+ T cells from PTX +VEH and PTX+TCDD groups as described in Methods. Of 
approximately 1111 miRNAs tested, 157 miRNAs were differentially expressed (Fold 
change > +/- 1.5) (Figure 5A). Proportional Venn diagram was generated to represent the 





upregulated (>1.5-fold) and 58 miRNA that were downregulated (>1.5-fold) in splenic 
CD4 T cells of PTX+TCDD group of mice, when compared to PTX+VEH group of mice 
(Figure 5B). Next, 106 miRNA that showed altered expression in PTX+TCDD group 
were analyzed using Ingenuity Pathway Analysis (IPA) software from QIAGEN. IPA 
pathway analysis showed several miRNAs that targeted the expression of cytokines, 
transcription factors, and signaling molecules related to inflammation (Figure 5C). Using 
Affymatrix Expression Console software, heat map of miRNAs of both groups was 
generated (Figure 5D). In addition, we analyzed miRNA-specific target genes using 
TargetScan and microRNA.org (www.microRNA.org) analytical tools available online. 
A list of target genes and their putative 3’UTRs (mRNAs/miRNAs) has been presented in 
Table 3. We identified miR-142-3p to target FoxP3, TGFβ2 and TGFβR1, miR-141-3p to 
target TGFβ2 and TGFβR1, miR-211-3p to target TGFβ1, TGFβ2, TGFβR1 and Smad2 
(Table 3). These data suggested that TCDD causes dysregulation of miRNA in T cells 
that target genes involved in inflammatory pathways.   
Validation of miRNAs by Quantitative Real-Time PCR (QRT-PCR)  
After analyzing miRNAs profile obtained from miRNA arrays, we selected 
several miRNAs, particularly that target cytokines production and Tregs proliferation, to 
validate their expression by QRT-PCR. We used the same RNAs from CD4+ T cells that 
we used for miRNA arrays. We validated the microarray data by using QRT-PCR of 
some select miRs that were up or down-regulated following TCDD treatment.  The data 
demonstrated that there was significant downregulation, miR-141-3p (Figure 5E, 
miR142-3p (Figure 5F), and miR-211-3p (Figure 5G) in splenic CD4 T cells from 





qRT-PCR to determine the expression miRNA target genes  
Next, we validated the gene expression of some of the targets of miRs disrupted 
by TCDD.   We noted significant upregulation of IL-10 (Figure 6A), TGF-β1 (Figure 
6B), TGF-β2 (Figure 6C), TGF-βR3 (Figure 6D), TGF-βR1 (Figure 6E), GATA3 (Figure 
6F), SMAD2 (Figure 6G) in cells from mice exposed to PTX+TCDD, when compared to 
PTX+VEH group.  Additionally, there was significant downregulation of IL-6 (Figure 
6H), and RORγT (Figure 6I) in PTX+TCDD group when compared to PTX+VEH group.    
Transfection studies to demonstrate the specificity of miR and their inflammatory 
target genes.  
  
During IPA analysis and using target scan, we observed that miR-1224-5p and 
miR-3082-5p had strong binding affinity with 3’UTRs of FoxP3 and IL-17, respectively 
(Table 3). To confirm that miR-1224 and miR-3082 specifically targeted FoxP3 and IL-
17 gene expression, respectively, we first performed QRT-PCR analysis of the expression 
of both miRs and potential targets from the same cell population namely, splenic CD4+ 
cells from PTX+VEH or PTX+TCDD. We noted significant upregulation of miR-3082-
5p (Figure 7A) and downregulation of miR-1224 (Figure 7E) in PTX+TCDD group when 
compared to controls.   Additionally, in the same cells, there was significant 
downregulation of IL-17 expression (Figure 7B) and increase in FoxP3 expression 
(Figure 7F) in PTX+TCDD groups when compared to controls. These data demonstrated 
that in the same cells, the miRNA expression induced by TCDD correlated with the 
expression of respective target genes involved in inflammation.   
To further confirm the role of miR-1224-5p and miR-3082-5p in the regulation of 
FoxP3 and IL-17, respectively, CD4+ T cells were transfected with either miR-1224-5p 





miR-3082-5p was determined by QRT-PCR. There was significant increase in the 
expression of miR-3802-5p and miR-1224-5p in cells transfected with miR-3082-5p 
mimic or miR-1224-5p mimic when compared to mock controls (Figure 7C, G).  
Inhibitors of miR-3082-5p and miR1224-5p completely blocked the expression of these 
miRs respectively (Figure 7C, G). In these cells, transfection with miR-3082-5p mimic 
led to significant downregulation of IL-17 while the inhibitor caused upregulation of IL-
17 (Figure 7D).  Furthermore, transfection of these cells with miR-1224-5p mimic led to 
downregulation of FoxP3 while the inhibitor caused increased expression of FoxP3 
(Figure 7H).  The data obtained from transfection experiment demonstrated a clear role of 
miR-1224-5p and miR-3082-5p in the expression of FoxP3 and IL-17 mediated by 
exposure to TCDD.  
4.5 DISCUSSION  
Bordetella pertussis is a human respiratory pathogen that causes whooping 
cough, and its virulence factor, pertussis toxin (PTX), promotes colonization leading to 
systemic disease (232).  Experimentally, PTX is well characterized as an adjuvant that 
promotes development of tissue-specific experimental autoimmune diseases such as 
experimental autoimmune encephalomyelitis (EAE), experimental autoimmune uveitis 
(EAU), and the like (233),(234).  PTX in these models, is known to enhance vascular 
permeability, damage to blood-brain barrier and induce Th1 responses (235), (236). More 
recent studies suggested that PTX can induce a robust Th17 response while inhibiting 
Tregs (64).  While the precise mechanisms through which PTX serves as a virulence 
factor in promoting B. pertussis infection is unclear, it is believed that the ability of PTX, 





pathology in the airways(60). Thus, agents that suppress such inflammation induced by 
PTX may help attenuate the pathogenesis.  In the current study, therefore, we tested the 
effect of TCDD, a potent AhR ligand on PTX-mediated inflammation.  Because the 
effect of TCDD on a potent toxin such as PTX known for its ability to promote Th1 and 
Th17 response while suppressing Tregs, has not been studies previously, we were 
interested to see if TCDD would reverse these effects and if so, identify the mechanisms.   
TCDD is described as the worst and most toxic human made environmental 
contaminant. TCDD is an environmental pollutant that mediates toxicity through 
activation of AhR, a ligand-dependent transcription factor and member of the basic helix-
loop-helix–Per/Arnt/Sim gene family (237, 238).  It is well characterized for its toxicity 
against the cells of the immune system (239-241). More recently, activation of AhR by 
TCDD has been shown to regulate differential expression of FoxP3 and IL-17 causing 
generation of more Tregs but suppression of Th17 cells (239), (242). The study from our 
lab has shown that TCDD suppressed EAE in mice (212). We have shown that TCDD 
modulated differential expression of IL-17 and FoxP3 in mice with EAE through 
epigenetic modifications (212). PTX, on the other hand, has been shown to promote the 
generation of Th17 cells (64). Because of opposite molecular functions of PTX and 
TCDD, we investigated whether TCDD can suppress PTX-induced inflammation in mice 
and examined the molecular mechanisms involved in TCDD-induced suppression of 
PTX-induced inflammation.   
In this study, we noted that injection of PTX triggered significant systemic 
inflammation in mice as evidenced by detection of several inflammatory cytokines in the 





detected in CD4+ T cells in the spleen.  Interestingly, the serum levels of IL-17 or 
proportion of Th17 cells in the spleens of PTX-treated mice was higher than that of IFN-γ 
or Th1 cells in the spleen, thereby demonstrating that PTX is a more potent inducer of 
Th17 cells than Th1 cells.  These data were consistent with the observation that PTX 
generates a cytokine storm associated with inflammation in mice by inducing IL-6 that 
promotes IL-17 production in CD4+ T cells (64). Also, our findings agree with previous 
observation that administration of PTX stimulates the development of pathogenic Th17 
cells in mice of immune-mediated ocular inflammation more than other TLR ligands, 
such as LPS, and polyinosinic-polycytidylic acid (243). In another study, it was reported 
that immunization with whole cell pertussis vaccination in mice resulted in the generation 
of Th17 cells (244). Previous studies, using mice infected with pertussis toxin (PTX)–
producing B. pertussis strain or an isogenic PTX-deficient strain (ΔPT), had shown that 
PTX activity was associated with upregulated expression of proinflammatory cytokines 
and chemokines (61) (232).  Studies on immunomodulation by B. pertussis have also 
shown that the host immune response may be tilted towards development Th17 cells, that 
produce IL-17A (64).   
In the current study, we noted that TCDD caused significant decrease in 
inflammatory (IL-17, IL-6, and IFN-γ) cytokines but an increase in anti-inflammatory 
(IL-10) cytokine in PTX-injected mice.  These data demonstrated that TCDD was able to 
suppress PTX-induced inflammation in mice. We noted increased switch from Th1 to 
Th2 phenotype with increased induction of IL-10 and TGF- following TCDD 
treatment.  IL-10 is an anti-inflammatory cytokine that is known to inhibit the activity of 





bet, the master regulator of Th1 cell differentiation (246). We also noted that TCDD was 
able to induce a switch from Th17 to Tregs in PTX-immunized mice.  This may result 
from decreased IL-6 seen in PTX+TCDD treated mice because IL-6-mediated STAT3 
signaling is essential for Th17 differentiation and plays a central role in the pathogenesis 
of certain autoimmune diseases such as rheumatoid arthritis (247).  The second 
mechanism through which TCDD may suppress Th17 cells may result from its ability to 
increase the expression of FoxP3 and induce more Tregs as seen in the current study 
using PTX and seen in other models autoimmune disease (248), (249). For example, 
TCDD was shown to suppress diabetes in NOD mice by increasing Foxp3+ T cells in 
pancreatic lymph nodes (249). Also, TCDD inhibited the clinical symptoms in an 
experimental autoimmune encephalomyelitis (EAE) model by inducing Tregs (68). 
Because EAE mouse models use PTX along with myelin oligodendrocyte glycoprotein 
(MOG) to enhance clinical signs of EAE, our studies raise an interesting question on 
whether TCDD-mediated suppression of EAE results from suppression of PTX effects or 
direct action on MOG-specific T cells. Previous studies from our laboratory has also 
shown that activation of AhR led to reciprocal epigenetic regulation of FoxP3 and IL-17 
expression and amelioration of experimental Colitis (239). In this study, we noted that 
there was decreased methylation of CpG islands of Foxp3 and increased methylation of 
IL-17 promoters, which led to increased induction of Tregs while suppressing Th17 
generation (239). In the current study, we noted that TCDD induced MDSC in PTX-
treated mice. Because Tregs have also been shown to be induced by MDSCs 
30103447,(250) this may constitute another additional mechanism through which Tregs 





PTX+TCDD-treated mice, it is possible that the increased IL-10 seen in these mice may 
have resulted from such Tregs that produce IL-10 (251). Previous studies from our lab 
reported TCDD-induced MDSCs generation in different tissues/organs like spleen and 
peritoneal cavity. Myeloid‐derived suppressor cells (MDSCs) are a heterogeneous 
population of immature myeloid cells that play a major role in immunosuppression in 
inflammation, cancer, and other diseases (252).  
In recent years, miRs have been shown to play an important role in the regulation 
gene expression and potentially may control majority of the molecular and cellular 
pathways (253-255). Also, specific miRs may play important roles in T cell and MDSCs 
development and functions by regulating target genes involved in their proliferation and 
differentiation (230). Previous studies from our lab have shown that AhR activation by 
dietary ligands such as indole-3-carbinol (I3C) or 3,3'-diindolylmethane (DIM) leads to 
decreased the expression of several miRs (miR-31, miR-219, and miR-490) that target 
Foxp3, while incresinga the expression of miR-495 and miR-1192 that target IL-17 (240). 
This leads to increased induction of Tregs and decreased differentiation of Th17 cells 
consequently suppressing delayed-type hypersensitivity (DTH) response to methylated 
BSA (240)  In another study, we noted that miRNA-466a-3p targeted TGF-β2 and 
regulated Treg differentiation (256). In the current study, we observed that PTX+TCDD 
group showed significant alterations in the expression of a numbers of miRNA and 
pathway analysis showed that some of these altered miRNAs targeted inflammatory 
cytokines or signaling pathways.  Interestingly, we were able to narrow down to some 
specific miRs that seemed to target FoxP3 and IL-17 gene expression through target 





affinity with 3’UTRs of FoxP3 and IL-17, respectively. We confirm the role of miR-
1224-5p and miR-3082-5p in the regulation of FoxP3 and IL-17, respectively, we 
performed transfection studies which conclusively demonstrated that miR-1224-5p and 
miR-3082-5p were involved in the upregulation of FoxP3 and down regulation of IL-17 
following exposure to TCDD.  The role of miR-1224-5p in the regulation of immune 
response has not been previously studied. MiR-1224-5p has been shown to act as a tumor 
suppressor by targeting CREB1 in malignant gliomas (257).  Similarly, the role of miR-
3082-5p has not been reported in any disease model.  Thus, our studies are unique in 
identifying for the first time that miR-1224-5p and miR-3082-5p play a role in the 
regulation of inflammation.   
In summary, our studies suggest that during PTX-induced inflammation, 
activation of AhR by TCDD may promote anti-inflammatory activity primarily through 
regulation of miRNA that target Foxp3 and IL-17 gene.  Because PTX plays a critical 
role in the pathogenesis of B. pertusis infection by inducing cytokine storm and 
exaggerated inflammatory response, our studies suggest that AhR ligands may serve as 








Figure 4.1 TCDD suppresses PTX-induced inflammation in mice. Mice were injected 
with PTX and TCDD as described in panel A and 4 days later, PTX+VEH or 
PTX+TCDD groups were investigated for inflammation.  (B)  ELISA was performed 
using sera collected from PTX+VEH and PTX+TCDD group of mice. Cytokines IL-17A 
(B), IL-6 (C), IFNγ (D), and IL-10 (E) were measured. Data are expressed as the mean ± 
S.E.M. and statistical significance is indicated as **p < 0.01, ***p< 0.001 and ****P < 






Figure 4.2 TCDD suppresses PTX-induced Th1 cells and promotes Th2 cells. Mice 
were immunized with PTX and injected with TCDD as described in Fig 1 legend.  
Splenocytes were double-stained for CD4 and various cytokines and analyzed by flow 
cytometry: (A) IL-10; (B)TGF-β; (C) IFN- .  Panels A-C show a representative 
experiment and data from multiple mice plotted in Panel D. Statistical analysis using 
Student’s t-test. Data are expressed as the mean ± S.E.M. and statistical significance 






Figure 4.3 TCDD promotes Treg while inhibiting Th17 induction. Mice were 
immunized with PTX and injected with TCDD as described in Fig 1 legend.  Splenocytes 
were double-stained for CD4 and FoxP3 or CD4 and IL-17 markers and analyzed using 
Flow cytometry.  Panel A shows a representative experiment while data from multiple 
mice plotted in Panel B, showing reciprocal regulation of Th17 vs Tregs between the two 






Figure 4.4 TCDD promotes MDSCs production.  Mice were immunized with PTX and 
injected with TCDD as described in Fig 1 legend.  Spleen cells were double-stained for 
Gr-1+CD11b+ cells.  Panel A shows a representative experiment while data from 
multiple mice is plotted in Panel B-C. Statistical analysis using Student’s t-test.  In Panel 
B-C data are expressed as the mean ± S.E.M. and statistical significance is indicated as 







Figure 4.5 MicroRNAs Analysis. Mice were immunized with PTX and injected with 
TCDD as described in Fig 1 legend.  Differentially expressed miRNA were analyzed in 
splenic CD4+ T cells. Total RNA was isolated and pooled from CD4+ T cells obtained 
from the spleen of PTX+VEH or PTX+TCDD groups (n = 5).  miRNA microarray assay 
was performed to test differentially expressed miRNA.  (A) The fold change distribution 
of the miRNAs found within CD4+ T cells from the spleen of PTX+Vehicle and PTX 
+TCDD mice. (B) Proportional Venn diagram illustrating fold change (>1.5) of miRNAs 
between the two groups. (C) Pathway analysis of miR mediating dysregulation in gene 
expression in PTX+TCDD group. (D) Heat map of hierarchical clustering of the relative 
expression of miRNA alterations. The color scale denotes those miRNAs that were 
upregulated (red) and downregulated (green). (E-G) Expression levels of select 






Figure  4.6 qRT-PCR validation of gene expression.  Mice were immunized with PTX 
and injected with TCDD as described in Fig 1 legend.  Expression of target genes was 
studied using qRT-PCR in CD4+ Tcells: (A) IL-10, (B) TGF-β1, (C)TGFβ2, 
(D)TGFβR3, (E) TGFβR1, (F) GATA3, (G) SMAD2, (H) IL-6 and (I) RORγt are 
shown, using GAPDH as a control. Data present mean ±SEM of 3 tests and statistical 
significance between the two groups was tested by Student’s t-test and p values were 






Figure 4.7 Role of miR-3082-5p and miR-1224-5p in regulating expression of IL-17A 
and FoxP3 respectively. T cells purified from splenocytes were analyzed as described in 
Fig 6: (A, B, E, F):  miRNA and target gene expression were analyzed by qRT-PCR. For 
transfection studies (C, D, G, H), splenic T cells were purified from naive B6 mice were 
cultured for 24 h transfected by nucleofection with miR-3082 inhibitor or mimic, and the 
expression of miRNA and target genes was analyzed using qRT-PCR. Data are presented 
as the mean ±SEM. Of experiments performed 3 times.  Statistical significance between 
the two groups was compared by Student’s t-test with p values indicated as follows:  *p< 






       Table 4.1 Up-regulated and down-regulated miRNAs upon TCDD exposure 











Table 4.2 mRNA related oligonucleotides that used in this study 
Gene     Forward Sequence (5′–3′)                        Reverse Sequence  (5′–3′)                  
Tgfβ1  CTCCCGTGGCTTCTAGTGC                GCCTTAGTTTGGACAGGATCTG 
Tgfβ2  CTTCGACGTGACAGACGCT               GCAGGGGCAGTGTAAACTTATT 
Tgfβr1 TCTGCATTGCACTTATGCTGA             AAAGGGCGATCTAGTGATGGA 
Tgfβr3 GGTGTGAACTGTCACCGATCA          GTTTAGGATGTGAACCTCCCTTG 
Il10   CCCATTCCTCGTCACGATCTC             TCAGACTGGTTTGGGATAGGTTT 
Foxp3 CCCATCCCCAGGAGTCTTG                 ACCATGACTAGGGGCACTGTA 
Smad2 ATGTCGTCCATCTTGCCATTC              AACCGTCCTGTTTTCTTTAGCTT 
Gata3 CTCGGCCATTCGTACATGGAA            GGATACCTCTGCACCGTAGC 
IL17a  TTTAACTCCCTTGGCGCAAAA             CTTTCCCTCCGCATTGACAC 
RORγt GACCCACACCTCACAAATTGA             AGTAGGCCACATTACACTGCT     
Il6      CCAAGAGGTGAGTGCTTCCC               CTGTTGTTCAGACTCTCTCCCT 





















5'   ...AUAAUUUAGCUCCCUACUCUGUU...    (Position 585-591) Targetscan     context++ score: -0.26 
                                                     |||||||                                            
3'       UGUGUCUGUGUGUGUGAGACAG     mmu-miR-3082-5p Targetscan context++ score percentile: 97 
IL-17AR  
5' ...GAGGGUGUAUAUUGUACUCUGUG...    (Position 38-44)    Targetscan     context++ score: -0.04 
                                                      |||||||  
  3'     UGUGUCUGUGUGUGUGAGACAG     mmu-miR-3082-5p Targetscan context++ score percentile: 81 
FoxP3  
5'    ...CAUGAUAGUGCCUGUGUCCUCAA...   (Position 1529-1536) Targetscan     context++ score: -0.16 
                                                      |||||||  
  3'         GAGGUGGAGGGGUCAGGAGUG    mmu-miR-1224-5p Targetscan context++ score percentile: 91 
  
   3'       agguauuucauccuuuGUGAUGu 5'      mmu-miR-142-3p mirSVR score: -0.0083 
                                                  |||||||  
1737:5' gccauucccccuuuucCACUACu 3'          FoxP3 PhastCons score: 0.4973 










5' ...GUCAGGUGUGUGGCUGUCCUUGA...   (Position 1529-1536) Targetscan     context++ score: -0.03 
                                               ||||||||||  
      3'      CGGGGGGAAACGACAGGAACG      mmu-miR-211-3p Targetscan context++ score percentile: 68 
TGFβR1  
5' ...UGACAUUUUUCCACUUCCUUGAG...    (Position 1529-1536) Targetscan     context++ score: - 0.02 
                                                   ||||||  
3'       CGGGGGGAAACGACAGGAACG           mmu-miR-211-3p Targetscan context++ score percentile: 45 
  
5'    ...UUAAAUUUCAUCCUAACACUACA... (Position 1529-1536) Targetscan     context++ score: - 0.44 
                                                      |||||||  
3'      AGGUAUUUCAUCCUUUGUGAUGU    mmu-miR-142-3p Targetscan context++ score percentile: 95 
  
5' ...UUUAUUUGAUCAAAGCAGUGUUU... (Position 1050-1056) Targetscan     context++ score: - 0.47 
                                                       |||||||  
3'         GGUAGAAAUGGUCUGUCACAAU     mmu-miR-142-3p Targetscan context++ score percentile: 98 
TGFβ2  




























                                                      |||||||                                
3'         GGUAGAAAUGGUCUGUCACAAU    mmu-miR-141-3p Targetscan context++ score percentile: 93 
  
5'    ...CUAGAUUUUGACUUGCACUACAA...(Position 1222-1228)  Targetscan     context++ score: - 0.17 
                                                         ||||||                    
3'      AGGUAUUUCAUCCUUUGUGAUGU   mmu-miR-142-3p Targetscan context++ score percentile: 76 
  
5' ...CUUAUCUGAGGAGCUGUCCUUGA.. (Position 2098-2105)  Targetscan     context++ score: - 0.13 
                                             ||||||||||                                                       
3'          CGGGGGGAAACGACAGGAACG      mmu-miR-211-3p Targetscan context++ score percentile: 89 
Smad2  
5' ...UGGAUUAACUUGGAAGUCCUUGA... (Position 581-588) Targetscan     context++ score: - 0.15 
                              |||                |||||||  






SUMMARY AND CONCLUSION 
Inflammation is involved in the pathogenesis of several clinical disorders 
including autoimmune, cardiovascular, and neurological diseases, obesity and cancer.  
Thus, identifying agents that suppress inflammation can have significant impact on 
human health.  In the current study, we used two unique models of inflammatory disease:  
1) Chronic inflammatory mouse model of EAE that mimics human MS, and 2) Acute 
mouse model of inflammation using PTX, a toxin produced by Bordetella pertussis that 
causes whooping cough.  In these models, we tested the role of activation of CB receptors 
and AhR, using select agonists such as cannabinoids (THC and CBD), or TCDD, 
respectively, to suppress inflammation. THC+CBD combination (Sativex) has been used 
to treat patients with MS for muscle spasticity.  However, whether it can also suppress 
neuro-inflammation and if so, the mechanism of action remains obscure. We demonstrate 
the effectiveness of these cannabinoids to ameliorate chronic inflammation, through 
unique mechanisms. The current study demonstrates for the first time that THC+CBD-
mediated suppression of neuroinflammation in EAE stems from alterations in miRNA 
expression and changes in microbiota.  Specifically, THC+CBD reduced cellular 
infiltration into the brain and spinal cord, decreased pro-inflammatory cytokines such as 
IL-17A, IFNγ, IL-6, TNF-α and IL-1β levels, while increasing anti-inflammatory IL-10 
and TGF-β. Also, THC+CBD prevented T cell expansion through induction of cell cycle 





suppresses neuro-inflammation and that this may be regulated by certain miRNA as well 
as alterations in the gut microbiota.  Importantly, these studies form the basis of targeting 
such miRNA and microbiota to treat MS. We also demonstrated that AhR activation by 
TCDD led to suppression of acute inflammation induced by Pertussis Toxin (PTX). PTX 
is an exotoxin that promotes bacterial invasion into the lungs and cause lung toxicity.  
Such toxicity results from cytokine storm involving pro-inflammatory cytokines such as 
IL-17A, IFNγ, and IL-6.  AhR activation decreased the production of these cytokines 
potentially through induction of immunosuppressive cells such as Tregs and MDSCs.  
AhR activation was also associated with alterations in the expression of miRNAs that 
promoted anti-inflammatory pathways.  It is interesting that activation of both CB 
receptors and AhR caused alterations in the expression of miRNA that targeted anti-
inflammatory pathways. Thus, the current study, by using CB and AhR signaling 
pathways, has identified new epigenetic pathways that can be targeted to suppress 
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